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Structural And Mechanical Responses To Intermittent Parathyroid Hormone 
Treatment, Discontinuation And Cyclic Administration Regimens 
Abstract 
Bone mineral density rapidly decreases upon withdrawal from intermittent parathyroid hormone (PTH) 
treatment despite its potent effect of promoting bone formation. To better understand this adverse 
phenomenon, this study first aimed to investigate the phenotype of PTH withdrawal in both intact and 
estrogen-deficient rat model by using a well-designed experiment combined with innovative longitudinal 
imaging techniques and localized cellular activities. Due to observing a continuous anabolic window upon 
early discontinuation of PTH treatment in estrogen-deficient animals, we propose a potential effective 
treatment strategy, the short cycles of PTH and antiresorptive treatment regimen, which could extend the 
anabolic windows by increasing the number of newly activated modeling-based bone formation (MBF) 
sites. Lastly, to understand the structure-function relationships of bone tissue formed through MBF 
compared to the remodeling-based bone formation (RBF), we developed an innovative imaging platform 
with a mechanical testing platform to determine the mechanical properties of MBF and RBF and their 
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STRUCTURAL AND MECHANICAL RESPONSES TO INTERMITTENT 
PARATHYROID HORMONE, DISCONTINUATION AND CYCLIC 
ADMINISTRATION REGIMENS 
Wei-Ju Tseng 
Dr. X. Sherry Liu 
Bone mineral density rapidly decreases upon withdrawal from intermittent 
parathyroid hormone (PTH) treatment despite its potent effect of promoting bone 
formation. To better understand this adverse phenomenon, this study first aimed to 
investigate the phenotype of PTH withdrawal in both intact and estrogen-deficient rat 
model by using a well-designed experiment combined with innovative longitudinal 
imaging techniques and localized cellular activities. Due to observing a continuous 
anabolic window upon early discontinuation of PTH treatment in estrogen-deficient 
animals, we propose a potential effective treatment strategy, the short cycles of PTH and 
antiresorptive treatment regimen, which could extend the anabolic windows by increasing 
the number of newly activated modeling-based bone formation (MBF) sites. Lastly, to 
understand the structure-function relationships of bone tissue formed through MBF 
compared to the remodeling-based bone formation (RBF), we developed an innovative 
imaging platform with a mechanical testing platform to determine the mechanical 
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Osteoporosis is a disease characterized by significant reductions in overall bone 
density and structural integrity, causing skeletal fragility and an increased risk of bone 
fractures [1]. Millions of people suffer from osteoporosis and related symptoms in the 
United States. According to the data from the National Health and Nutrition Examination 
Survey, 2005 to 2010, 10.3% or 10.2 million adults over 50 years old in the United States 
had osteoporosis at the femoral neck or lumbar spine [2]. Current osteoporosis treatments 
focus on either inhibiting bone resorption using antiresorptive agents or promoting bone 
formation using anabolic treatments [3]. However, due to bone formation-resorption 
coupling mechanisms, drugs inhibiting bone resorption often indirectly reduce formation, 
and those increasing formation also induce resorption, thereby limiting their potential 
benefits [3]. Therefore, it is of great interest to understand the mechanisms behind 
existing treatment options to better develop effective clinical treatment strategies [4]. 
Recombinant human parathyroid hormone (rhPTH) 1-34 is the first FDA-
approved anabolic treatment for postmenopausal women and men who are at a high risk 
for fracture [5, 6]. Daily PTH administration can rapidly increase bone mass and restore 
bone microarchitecture of trabecular bone [7, 8]. However, despite the potent effects of 
PTH, clinical studies showed a rapid decline in bone mineral density (BMD) and bone 
formation markers upon withdrawal of PTH treatment [9]. In addition to BMD and serum 
markers, there is limited information on bone microarchitecture and cellular activities 
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after discontinuation of PTH treatment. Therefore, this thesis first aimed to uncover the 
structural and biological changes behind this adverse phenomenon by using a well-
designed experiment combined with innovative longitudinal imaging techniques and 
localized cellular responses. 
In clinical practice, the recommended treatment duration of PTH administration is 
limited to 18-24 months due to its corresponding safety concerns such as osteosarcoma 
[10-13]. Thus, it is of great clinical interest to combine the PTH with antiresorptive 
treatment to maximize PTH efficacy by inhibiting osteoclast resorption. However, several 
studies expressed concerns over the effectiveness of concomitant use of PTH and 
antiresorptive agents [9, 14, 15]. We found a continuous anabolic window during the first 
week of PTH discontinuation in an ovariectomized (OVX) rat model followed by a 
significant increase in osteoclast number in the first study. This result led to the 
hypothesis that the short cycles of PTH treatment may extend the treatment duration and 
incorporation with an antiresorptive treatment during the off-PTH period of cyclic 
treatment regimen may further improve the treatment effectiveness of PTH. Therefore, 
we propose a potential therapeutic treatment strategy, cyclic and alternating treatment 
regimens of daily injection of PTH and alendronate (ALN). Indeed, clinical studies have 
tested on this strategy and suggested that short PTH cycles could potentially dissociate 
the early PTH-induced anabolic effects on modeling-based bone formation from the latter 
effects on remodeling-based bone formation. 
Recent studies identified the activation of modeling-based bone formation (MBF) 
as a vital mechanism as a result of rapidly increasing new bone formation by anabolic 
agents for osteoporosis [16], such as PTH [17-19] and sclerostin-neutralizing antibody 
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(Scl-Ab) [20]. In addition to treatment with an anabolic agent alone, studies have also 
shown that MBF can be elicited on the trabecular bone surface by PTH with co-treatment 
of an anti-resorptive drug [19, 21-27]. However, the quality, i.e., structural and 
compositional heterogeneity, of bone tissue on the trabecular bone surface generated 
through MBF is not fully understood, partially due to the difficulty in distinguishing these 
types of formation on thick bone sections. The only difference that the literature reported 
between MBF and remodeling-based bone formation (RBF) is structural morphometry on 
thin sections [28]. Thus, in this thesis, we developed an imaging method that can be 
coupled with a mechanical testing platform for reliable identification and examination of 
mechanical properties of MBF and RBF on thick bone sections. 
1.2 Background 
1.2.1 Bone structure, composition and mechanical properties  
Bone is a composite material with a complex, hierarchical structure from the 
molecular to the macroscopic level (Figure 1-1) [29, 30]. Bone skeleton plays a 
significant biomechanical role by providing structural support and protecting organs and 
tissues [30, 31]. The skeleton system also serves as a major reservoir for mineral ions to 
maintaining homeostasis and acid-base balance, and for growth factors and cytokines as 
well as a compartment for generating and storing cells [30-33]. Bone tissue consists of an 
inorganic and an organic phase. By weight, bone tissue consists of  ~60% inorganic 
matrix, ~30% organic matrix, and ~10% water [29-32]. By volume, these proportions are 
approximately 40%, 35% and 25%, respectively [30]. An inorganic phase is an impure 
form of hydroxyapatite, Ca10(PO4)6(OH)2, a naturally occurring calcium phosphate [29-
32]. On the other hand, the organic phase is composed of ~90% type I collagen and ~10% 
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noncollagenous proteins, such as proteoglycans and glycoproteins [29-32]. These 
molecular constituent elements at the sub-nanostructure level (below a few hundred 
nanometers scale) are assembled to comprise the mineralized collagen fibrils. These 
fibrils are laid down in lamellar pattern in alternating orientation, which are further 
assembled into two distinct bone structures: (1) compact (cortical) bone assembled from 
haversian systems (3-7 µm scale) and osteons (10-500 µm scale), and (2) cancellous 
(trabecular) bone assembled from hemiosteons (or called packets) (3-7 µm scale) and 
single trabeculae (10-500 µm scale) [29-32]. In the adult skeleton, the compact bone and 
the cancellous bone are approximately 80% and 20%, respectively [29-33]. The compact 
bone has a porosity of about 10% with 12-18GPa elastic moduli, while the cancellous 
bone is a highly porous structure with 50-95% porosity with lower mechanical properties 
ranging from 100 to 500MPa [29, 30]. 
1.2.1.1 Tissue-level Mechanical Properties 
Tissue-level mechanical properties include the tissue-level elastic modulus, 
toughness, and hardness that can be measured in microstructure, sub-microstructure and 
nanostructure levels. Indentation is a mechanical testing technique that can evaluate such 
properties, i.e., using a tip with known geometry and properties to press into a flat, 
smooth specimen surface whose properties are unknown [34, 35]. The indentation load-
displacement curve can be derived, thus determining mechanical properties. Briefly, the 
applied load on the indenter tip is increased while the tip penetrates further into the flat 
and smooth specimen surface until the desired penetrated displacement. The maximum 
indentation load is then held for a period of time to reduce the creeping effect prior to 
unloading [36, 37]. The load and tip displacement are recorded by the system, as shown 
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in Figure 1-2. Therefore, hardness and elastic modulus of the specimens can be calculated 
using the Oliver and Pharr method based on the initial unloading portion of the load-





where H is the contact hardness (GPa), Pmax is the peak indenting load (µN), and A is the 
projected contact area (mm2) [34, 35]. The elastic modulus of the test specimen, Es, is 





where β is a constant that depends only on the geometry of the indenter. β for the 
Berkovich indenter is 1.034. S is the experimentally measured contact stiffness or the 













where reduced modulus (Er) is measured by calculating the unloading slope from 
the displacement-force curve. The indices s and i refer to the specimen and the indenter 
material, respectively, and vs is Poisson’s ratio of the test specimen. Since the indenter tip 
is made of diamond, the typical modulus Ei and the poison ratio value vi of diamond are 
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1141 GPa and 0.07, respectively. Poisson’s ratio of bone is assumed to be 0.3 based on 
previous studies [38]. 
1.2.1.2 Whole Bone Mechanical Properties 
 Whole-bone mechanical properties include peak load, displacement, energy to 
failure, and stiffness that can be directly measured by 3- or 4-point bending and 
compression testing through evaluation of the force-displacement curve [39, 40]. The 
apparent-level stress, strain, modulus, toughness, and ultimate stress can be derived based 
on the dimensions of tested bone specimens. In addition, shear properties can be 
evaluated by the torsional testing, and the fatigue life and microdamage can be 
determined by the fatigue testing. 
1.2.2 Bone cells: Osteoblasts, osteoclasts, and osteocytes 
Three major cell types involved in formation and resorption are osteoblasts, 
osteoclasts, and osteocytes. Osteoblasts are mononuclear cells derived from 
mesenchymal cells and resided on the bone surfaces to form new bone tissue [30, 31]. 
Osteoblasts are generally cuboidal cells with 20-30 μm width and 10 μm tall [30, 31] but 
they may also form other shapes, including a rounded shape, an oval shape or a 
polyhedral shape. Osteoblasts synthesize and secrete mostly type I collagen and proteins, 
including osteopontin, osteocalcin, cytokines, and growth factors as well as producing 
and regulating calcium phosphate minerals [31, 33]. The adult osteoblasts transform into 
osteocytes or undergo apoptosis [31]. Osteoclasts are highly specialized multinucleated 
cells derived from the hematopoietic cell precursors in the bone marrow and peripheral 
blood [30, 31]. Osteoclasts are large multinucleated cells with 1 to 50 nuclei with a 
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diameter of 20-100 μm [30, 31]. Osteoclasts reside on the bone surfaces to break down 
both inorganic and organic bone matrix by acidification and enzymatically degrade 
demineralized bone [31, 33]. Osteocytes are mature cells of osteoblasts embedded in the 
mineralized matrix, which are more than 90% of bone cells in adult bone [41]. A single 
osteocyte resides in lacunae that connect and communicate with neighboring cells 
through canaliculi [30, 31, 41]. In the lacunae and canaliculi system, osteocytes sense and 
respond to fluid flow shear stress or mechanical stimuli producing signaling molecules to 
regulate osteoblasts and osteoclasts and to adjust bone formation and resorption [30-32, 
41].  
1.2.3 Bone modeling and bone remodeling 
Bone modeling and remodeling are inherently involved in the alteration of bone in 
response to environmental changes [33]. Bone modeling or so-called modeling-based 
bone formation (MBF) is a process that primarily alters overall bone size and shape in 
response to physiologic influences, e.g., skeleton growth, healing, and external 
mechanical stimulation [16, 31, 33]. During MBF, formation and resorption are not 
tightly coupled, i.e., de novo bone formation without prior activation of osteoclastic 
resorption (Figure 1-2) [16, 28, 42]. Since MBF occurs on quiescent bone surfaces 
without preceding bone resorption, the MBF site is characterized as a new bone packet 
with a smooth cement line without interruption of the surrounding collagen fibers [28, 
43]. Bone remodeling or so-called remodeling-based bone formation (RBF), on the other 
hand, plays a predominant role in maintaining skeletal health and mineral homeostasis 
[28, 33]. During RBF, formation and resorption are tightly coupled, i.e., new bone 
formation over the resorbed bone surface (Figure 1-2) [16, 28, 33, 42]. Due to bone 
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resorption preceding bone formation, the RBF site is characterized as a scalloped cement 
line with interruption of surrounding cement lines [28, 43]. 
1.2.4 Osteoporosis 
Bone is a dynamic tissue that is continuously remodeled to adapt to mechanical 
stimuli and repair through osteoclast-based bone resorption and osteoblast-based bone 
formation. Since bone resorption and bone formation are coupled, there is no change in 
overall bone quality over time. However, when the regulation becomes a net imbalance 
towards resorption due to aging or environmental changes, it may result in severe 
metabolic bone diseases, such as osteoporosis [33]. A characteristic feature of 
osteoporosis is significant reductions in overall bone density and structural integrity, 
causing skeletal fragility and increased risk of bone fractures [1]. In the United States, 
with millions of people suffering from osteoporosis and related symptoms, osteoporosis 
is one of the leading causes of morbidity in the aging population [1]. According to the 
data from the National Health and Nutrition Examination Survey, 2005 to 2010, 10.3% or 
10.2 million adults over 50 years old had osteoporosis at femoral neck or lumbar spine 
[2]. There are several types of osteoporosis. Postmenopausal osteoporosis in women, also 
called primary type 1 osteoporosis, is the most common form of osteoporosis. Primary 
type 2 osteoporosis due to aging occurs in both females and males. Additionally, 
medicines, e.g., cancer chemotherapeutic drugs and glucocorticoids, may lead to bone 
loss, which is referred to as secondary osteoporosis. The common sites that are 




1.2.5 Osteoporosis Treatment 
 Current osteoporosis treatments focus on either inhibiting bone resorption using 
antiresorptive agents or promoting bone formation using anabolic treatments. 
Antiresorptive agents target to inhibit the activities of osteoclasts, reducing bone 
resorption [3]. Anabolic agents, on the other hand, act by stimulating new bone formation 
[3].  
1.2.5.1 Antiresorptive Agents  
Antiresorptive agents are an osteoporosis treatment that prevents bone loss by 
inhibiting bone resorption, decreasing osteoclast formation and increasing osteoclast 
apoptosis [44, 45]. Bisphosphonates are among the most commonly prescribed drugs to 
reduce bone loss, preventing fractures in postmenopausal women and men with 
osteoporosis [44, 46, 47]. However, recent studies indicated that the use of 
bisphosphonates is associated with atypical subtrochanteric and femoral shaft fractures 
[46, 47]. Estrogens suppress bone resorption, leading to increased BMD and bone 
strength by blocking cytokine signals that activate osteoclasts [44]. Therefore, estrogen 
replacement therapy effectively treats postmenopausal osteoporosis since it adds estrogen 
to circulation to replace the loss of estrogen. However, due to the increased risks of 
cancer and stroke, it is not as commonly used [44]. Selective estrogen receptor 
modulators act on subclasses of estrogen receptors, inhibiting bone resorption by 
blocking cytokine signals that activate osteoclasts [44]. An example of a selective 
estrogen receptor modulator is raloxifene and tamoxifen [44]. Calcitonin is a non-sex, 
non-steroid hormone that binds explicitly to osteoclasts to inhibit cytoskeletal function in 
osteoclasts, thereby decreasing osteoclasts activities [44]. However, calcitonin treatment 
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shows less effectiveness in bone turnover compared to other antiresorptive agents [44]. 
Denosumab is a humanized monoclonal antibody that binds to the receptor activator of 
nuclear factor κB ligand (RANKL), inhibiting the activation of mature osteoclasts and the 
development of preosteoclasts [44, 45]. Cathepsin K is an enzyme expressed by 
osteoclasts that degrades type 1 collagen. Odanacatib is a highly selective cathepsin K 
inhibitor, thereby blocking osteoclast resorptive activity. In addition to this specific 
function, odanacatib does not affect the signaling mechanisms or other functions than the 
bisphosphonates and the RANKL inhibitor, denosumab [45]. 
1.2.5.2 Anabolic Agents 
Parathyroid hormone (PTH) is an endocrine factor secreted by the parathyroid 
glands to regulate bone remodeling [48, 49]. Interestingly, PTH shows the two 
completely opposite bone metabolisms [48, 49]. Dobnig and Turner reported in a rat 
model that continuous infusion of PTH caused bone resorption, whereas intermittent 
administration of PTH resulted in bone formation [50]. This anabolic observation led to 
the development of teriparatide, a synthetic form of PTH, the first anabolic agent 
approved by the FDA for osteoporosis treatment [5]. However, due to its theoretical risks 
on osteosarcoma development, the recommended duration of PTH treatment is limited to 
18-24 months in clinical practice [10-13]. Abaloparatide is the second FDA-approved 
anabolic agent [51]. Abaloparatide, a PTH analog, is a 34-amino acid peptide with 65% 
homology with parathyroid hormone-related protein (PTHrP) (residue 1-22) and 41% 
homology to PTH (1–34) [45]. Abaloparatide is a potent and selective activator of the 
PTHR1 signaling pathway with greater bone formation effects than bone resorption to 
maximize the anabolic window [45, 52]. Romosozumab (Scl-Ab), a humanized 
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monoclonal antibody to sclerostin that binds to sclerostin, is the third FDA-approved 
anabolic agent [53]. Sclerostin, a glycoprotein produced primarily by osteocytes, blocks 
the canonical Wnt signaling bone formation pathway, increasing bone formation and 
bone mineral density (BMD) [20, 45, 54]. 
1.3 Significance of Studies 
Teriparatide (rhPTH1-34) is the first FDA-approved anabolic treatment of 
osteoporosis in postmenopausal women and men at a high risk of fracture [5, 6]. 
Although daily PTH administration can efficiently stimulate new bone formation and 
rapidly increase bone mass, the improvement in bone mass may disappear after treatment 
stops [9]. It is imperative to maximize the anabolic response on bone after 
discontinuation of PTH administration. However, there is limited knowledge about this 
adverse event. Therefore, the mechanisms behind this adverse phenomenon are addressed 
using an in vivo imaging method, and cellular approaches in this thesis. This study is 
significant because it improves the understanding of discontinuation of PTH treatment 
and thereby may provide a clinical insight to develop a potential therapeutic treatment 
strategy for osteoporosis treatment. 
 In clinical practice, the recommended treatment duration of PTH administration is 
limited to 18-24 months due to its corresponding safety concerns such as osteosarcoma 
[10-13]. It is of great clinical interest to combine the PTH with antiresorptive treatment to 
maximize PTH efficacy by inhibiting osteoclast resorption. However, several studies 
expressed concerns over the effectiveness of concomitant use of PTH and antiresorptive 
agents [9, 14, 15]. As a result of observation of a continuous anabolic window during the 
first week of PTH discontinuation in an estrogen deficient rat model followed by a 
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significant increase in osteoclast number, a short cycle of PTH and antiresorptive 
treatment regimen may further improve the treatment effectiveness of PTH treatment. 
Therefore, we propose a potential therapeutic treatment strategy, cyclic and alternating 
treatment regimens of a daily injection of PTH and alendronate (ALN). This study 
provides clinical insight to maximize the treatment efficacy of PTH and allows for 
extended the treatment duration. 
In addition to its clinical implications, this study also improves the current 
understanding of the nanomechanical properties of PTH-induced bone formation, both 
modeling-based bone formation (MBF) and remodeling-based bone formation (RBF). 
Clinical studies suggested that the short cycles of PTH treatment could potentially 
dissociate the early modeling-based anabolic effect from the latter remodeling-based 
effect, thereby leading to increasing the number of newly activated MBF sites. However, 
in addition to the structural morphometry, the quality, i.e. structural and compositional 
heterogeneity, of bone tissue on the trabecular bone surface generated through MBF and 
RBF and their long-term contributions are not fully understood. Therefore, the 
investigation is the first attempt to answer several clinically important questions 
regarding the long-term therapeutic potentials of MBF and RBF: (1) what happens to the 
newly formed bone after PTH administration? (2) which type of newly formed bone 
(MBF vs. RBF) will have better nanomechanical properties after secondary 
mineralization? An understanding of the mechanical functions of bone tissue formed 
through MBF and RBF and its long-term contributions to maintaining bone strength 
provide critically important insight into long-term management of osteoporosis.  
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1.4 Specific Aims 
Aim 1: To evaluate the structural and biological changes in both intact and 
estrogen-deficient rat bone in response to discontinuation of daily PTH treatment. 
The estrogen-deficient rat model will be used to simulate postmenopausal bone loss. We 
hypothesize that a distinct phenotype may be observed by PTH withdrawal in both intact 
and estrogen-deficient rats. Changes in intact and estrogen-deficient rats’ bone 
microarchitecture will be directly measured through assessment with in vivo µCT for 
both PTH treatment and withdrawal. The mechanisms behind the phenomenon in bone 
microarchitecture will be investigated through measurement of osteoblast- and osteoclast- 
activity to determine how PTH discontinuation significantly impacts cellular activities. 
Aim 2: To investigate the effect of a potential treatment strategy of cyclic and 
alternating daily PTH injections and antiresorptive treatment on bone 
microarchitecture in estrogen-deficient rats. Our results in Aim 1 showed a continuous 
anabolic window one week after discontinuation of PTH followed by an increase in 
osteoclast number. Therefore, we hypothesize that incorporation of an antiresorptive 
treatment with a cyclic PTH treatment regimen will improve the treatment efficacy. 
Changes in bone microarchitecture of OVX rats will be directly measured and assessed 
using in vivo µCT. The trabecular structure and strength at lumbar vertebrae and femoral 
midshaft cortical bone will be evaluated and compared between different treatment cycle 
regimens. Results of this study could lead to a potential clinical application. 
Aim 3: To determine the nanomechanical properties of bone tissue from MBF and 
RBF and long-term contributions to maintain bone strength. Based on the structural 
morphometry, we hypothesize that the homogeneous collagen structure of MBF site may 
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lead to reduced heterogeneity of tissue material properties when compared to RBF sites. 
Long-term MBF and RBF properties and mechanical strength after secondary 
mineralization will be quantified by using a newly developed microscopic imaging 
platform and a nano-scale mechanical testing approach on adult intact rats treated with 
PTH. 
1.5 Study Design 
All experiments were approved by the University of Pennsylvania's Institutional 
Animal Care and Use Committee. A total of 135 Sprague-Dawley (SD) rats were used in 
this thesis. The SD rat is a commonly used model to study skeletal physiology and 
pathophysiology [55, 56]. In addition, the trabecular bone of the adult rat has an average 
bone volume fraction (BV/TV) of ~0.3 and trabecular thickness (Tb.Th) of 0.075 mm at 
the proximal tibia which is adequate for precise, longitudinal tracking of microstructural 
changes by in vivo μCT [57]. All rats were purchased from Charles River at 3 months of 
age and were housed at the University of Pennsylvania’s University Laboratory Animal 
Resources facility. The experiment started when female rats were at the age of 16-17 
weeks or at the age of 7 months. Although the long bones of rats continue to grow over 
time due to not closing the growth plate, rats at the age of 16-17 weeks grow slower and 
are able to use for ovariectomy (OVX) surgery in Aim 1 and Aim 2. At the age of 7 
months, there is minimal bone growth at this age. Therefore, we used 7-month-old rats in 
Aim 3. 
Aim 1 focused on longitudinally tracking changes in bone microarchitecture for 
treatment and discontinuation on estrogen deficient rats. Rats used in Aim 1 received 
OVX surgery at age 16-17 weeks to induce estrogen deficiency. The right proximal tibia 
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of all rats was scanned using in vivo μCT and changes in bone microstructure were 
evaluated. A cross-sectional study was also performed to observe the cellular activities, 
including that of osteoblasts, osteoclasts and adipocytes. In addition, serum was collected 
and evaluated for tartrate-resistant acid phosphatase (Serum TRAcP 5b), a marker of 
bone resorption. 
Aim 2 investigated the effect of a different treatment strategy of cyclic and 
alternating antiresorptive treatment and daily PTH injections on bone microarchitecture 
in estrogen-deficient rats. Rats used in this portion of the study received OVX surgery at 
age 16-17 weeks to induce estrogen deficiency. We longitudinally tracked changes in 
bone microarchitecture on the right proximal tibia. In addition, we evaluated the bone 
microarchitecture and whole-bone mechanics on the midshaft region of the right femur 
and the L2 lumbar vertebrae. 
Aim 3 determined the mechanical properties of bone tissue from MBF and RBF 
and long-term contributions to maintain bone strength. Rats used in Aim 3 received 
multi-fluorochrome labels at the age of 7 months. A novel microscopic imaging platform 
including fluorescence imaging, second harmonic generation imaging using a 
multiphoton microscope, and brightfield imaging was first developed to identify MBF 
and RBF on thick bone sections. Using this newly developed imaging platform and a 
nano-scale mechanical testing approach, the mechanical properties in both MBF and RBF 
were quantified after secondary mineralization. Finally, the quantification of bone 
mineralization was evaluated on MBF and RBF sites using backscattered scanning 
electron microscopy (SEM) images. 
Power analyses were performed to estimate the required group sizes. Based on an 
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estimated variance in the measured parameters of around 20%, and an expected 
intergroup 
difference of at least 30%, we anticipated that a sample size of 6-10 animals per 
group would allow for a type I error rate of 5% and a statistical power of 80%. 
1.6 Chapter Overview 
Chapter two will describe the experimental studies to uncover the structural and 
biological changes behind the discontinuation of PTH by longitudinal tracking the 
changes in trabecular bone microarchitecture and localized cellular responses at the 
proximal tibia in an intact rat model and an OVX rat model. Chapter three will describe 
studies investigating effectiveness of the short cycles of PTH treatment and incorporating 
an antiresorptive treatment during the off-PTH period of cyclic treatment regimen. We 
propose a potential therapeutic treatment strategy, cyclic and alternating treatment 
regimens of alendronate (ALN) and daily injection of PTH. Chapter four will describe a 
novel imaging method that can be coupled with a mechanical testing platform to reliably 
identify and examine material properties of RBF and MBF on thick bone sections. 
Finally, chapter five will summarize the overall conclusions of this thesis and will discuss 











































































































































































Cyclic Treatment Regimen Rescues Parathyroid Hormone Discontinuation-Induced 
Bone Loss and Microarchitecture Deterioration in Ovariectomized Rats 
 
2.1 Introduction 
 Osteoporosis is a disease characterized by significant reductions in overall bone 
density and structural integrity, causing skeletal fragility and an increased risk of bone 
fractures [1]. Risks of osteoporosis and fragility fracture significantly increased in women 
post menopause, as rapid decline in estrogen levels during menopause leads to 
accelerated bone resorption that outpaces bone formation. Current treatments for 
postmenopausal osteoporosis focus on either inhibiting bone resorption using anti-
catabolic agents or promoting bone formation using anabolic treatments [2]. Teriparatide, 
recombinant human parathyroid hormone (rhPTH) 1-34, is the first FDA-approved 
anabolic agent for osteoporosis when administered intermittently. This anabolic agent is 
approved for the treatment of osteoporosis in postmenopausal women and in men at high 
risk of bone fracture [3, 4]. Unlike the anti-resorptive agents which suppress bone 
resorption through inhibition of osteoclast activities, its mechanism of action is to 
promote bone remodeling and to shift the balance of remodeling towards increased bone 
formation [5-7], thereby rapidly increasing bone mass and reducing the risk of fractures.  
 In clinical practice, the recommended duration of PTH treatment is limited to 18-
24 months due to its theoretical risks on the development of osteosarcoma [8-11]. 
However, osteoporosis in postmenopausal women and elderly men is a life-long, chronic 
condition. Despite the potent effect of PTH on promoting new bone formation, if not 
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followed by an antiresorptive agent, the gains in bone mineral density (BMD) were 
quickly lost upon withdrawal from PTH treatment [12-14]. In a randomized, 2-year study 
with a 1-year treatment of PTH1-84 followed by a 1-year treatment of alendronate or 
placebo, women who were randomly given a placebo after PTH treatment experienced a 
nearly 2% loss in BMD at the spine. Moreover, trabecular bone is more susceptible to the 
bone loss upon PTH discontinuation, demonstrated by a striking 10% decrease in the 
trabecular volumetric BMD at the spine. However, mechanisms behind this adverse event 
is not clear. To maximize the efficacy of PTH, it is imperative to obtain a better 
understanding of the mechanisms behind the bone loss upon discontinuation from PTH 
treatment. Therefore, the first objective of this study was to establish a rat model to study 
the structural changes and cellular responses after discontinuation of intermittent PTH 
administration in both intact and estrogen deficient rats. By using an in vivo μCT imaging 
technique with high spatial and temporal resolution, we discovered a continuous anabolic 
window of bone gain upon early withdrawal from PTH treatment in the estrogen-
deficient rats, which was further confirmed by histological analyses of bone cells. The 
anabolic window would offer a new mechanism in support of the cyclic PTH treatment 
regimen to maximize the anabolic effect of PTH and extend treatment duration. With this 
being said, the second objective was to test the efficacy of a cyclic PTH treatment 
regimen on rescuing PTH's withdrawal effects. We hypothesized that a cyclic PTH 
treatment regimen with repeated cycles of on and off daily injection of PTH would best 
utilize the anabolic window upon withdrawal, resulting in extended treatment duration 




2.2. Materials and Methods 
2.2.1 Animals and treatment plans 
 All experiments were approved by the University of Pennsylvania's Institutional 
Animal Care and Use Committee. A total of 101 female Sprague Dawley rats were used 
in this study. Rats were randomly assigned to different groups, housed in standard 
conditions in groups of three rats per cage. Experiments were performed unblinded. 
Intermittent PTH treatment (Human Recombinant PTH1-34, Bachem, Bubendorf, 
Switzerland) was administered subcutaneously 5 times per week to all animals at the dose 
of 40 µg/kg/day while Vehicle treatment was administered in the form of subcutaneous 
injections of saline (150 μL/day, 5 times per week). 
 To study the skeletal effect of PTH discontinuation, 40 intact female rats and 42 
ovariectomized rats (OVX) were used. The study of intact rats began when the rats were 
at 16-17 weeks old. First, a longitudinal μCT imaging study was performed for a vehicle 
group (V3V9, receiving saline injections for 12 weeks, n=6) and a PTH-VEH group 
(P3V9, receiving injections of PTH for 3 weeks followed by saline for 9 weeks, n=6, 
Figure 2-1A) where animals received in vivo μCT scans every 3 weeks. Second, 
additional μCT scans were performed for a vehicle group (V3V3, n=5) and a PTH-VEH 
group (P3V3, n=3, Figure 2-2A) at week 0, 3, 4, 5, 6 for detecting skeletal response 
immediately after treatment discontinuation. Next, 20 rats were used in a histology study 
to assess bone cell activities in response to discontinuation of PTH and euthanized after 
3-week VEH treatment (V3, n=5), 3-week PTH treatment (P3, n=5), 3-week PTH 
treatment followed by 1-week VEH treatment (P3V1, n=5), and followed by 2-week 
VEH treatments (P3V2, n=5).  
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 Rats in the OVX group received a bilateral ovariectomy (OVX) surgery at 16-17 
weeks of age. The study began after a 4-week development of osteoporosis in the OVX 
rats. Similar to the intact rats, 18 OVX rats were assigned to 2 groups for a longitudinal 
μCT imaging study: a vehicle (OVX-V3V9, n=9) group receiving saline injections for 12 
weeks and a PTH-VEH group (OVX-P3V9, n=9) receiving PTH injections for 3 weeks 
followed by saline for 9 weeks (Figure 2-3). In vivo μCT scans were performed at week -
4, 0, 3, 4, 5, 6, 8, 10, and 12. Additionally, 24 rats were used to assess bone cell activities 
after 3-week VEH treatment (OVX-V3, n=6), 3-week PTH treatment (OVX-P3, n=6), 3-
week PTH treatment followed by 1-week VEH treatment (OVX-P3V1, n=6), and 
followed by 2-week VEH treatments (OVX-P3V2, n=6).  
To test efficacy of long-term treatment regimens, 20 OVX rats were assigned to 3 
groups:  VEH (18-week saline injections, n=6), PTH-VEH (9-week PTH treatment 
followed by 9-week vehicle treatment, n=7), and Cyclic PTH (3-week PTH followed by 
3-week vehicle treatment, repeat for 3 cycles, n=7).  
2.2.2 In vivo µCT scans and analysis 
 As described in [15] and [16], rats were anesthetized (4.0/2% isoflurane), and the 
right leg of each rat was inserted into a custom holder to prevent movement during the 
scan. A 4-mm region of the tibia, distal to the proximal growth plate, was scanned at 10.5 
μm voxel size, 55 kVp energy, 145 µA intensity, 200 ms integration time, and 1000 
projections, using a 0.5mm Al filter and a standard, manufacturer-provided beam-
hardening correction algorithm, resulting in a total scan time of about 20 minutes and 
approximate radiation dose of 0.639 Gy per scan. 
27 
 
 The follow-up scans were registered to the baseline scan following procedures as 
described in our previous publications [15, 17]. Briefly, a volume of interest (VOI) of 
trabecular bone compartment in the secondary spongiosa, starting approximately 2.3 mm 
distal from the growth plate and consisting of 200 slices (corresponding to a 2.1 mm thick 
section) was chosen in the last scan. By applying 3D image registration [15, 17], the 
corresponding VOIs of trabecular bone in images from the previous time points were 
precisely identified. Representative baseline and registered follow-up images of each 
treatment group are shown in Figure 2-1B and 2-3B. 
 Bone voxels of each registered image were segmented from the bone marrow and 
background using Gaussian filtering (sigma=1.2 and support=2.0) and a global threshold 
corresponding to 564.8 mgHA/cm3. Bone microstructural parameters including bone 
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), 
trabecular number (Tb.N), structure model index (SMI), and connectivity density 
(Conn.D), were evaluated for all registered VOIs. 
2.2.3 Bone histomorphometry and serum biochemistry analysis 
The right tibiae in the V3, P3, P3V1, and P3V2 group of intact and OVX rats 
were harvested immediately after euthanasia for methylmethacrylate (MMA) embedding. 
Five-µm-thick longitudinal sections were cut using a Polycut-S motorized microtome 
(Reichert, Heidelberg, Germany) for static bone histomorphometry measurements. 
Goldner's trichrome staining was performed to identify osteoblasts, osteoclasts, and bone 
surface. Furthermore, for estrogen-deficient rats, the left tibia was harvested for paraffin 
embedding. Five-µm-thick longitudinal paraffin sections were sectioned. Hematoxylin 
and eosin (H&E) staining was performed to identify adipocytes and bone marrow area. 
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All histomorphometric measurements were performed in an area 2.0–5.0 mm distal to the 
growth plate using Bioquant Osteo Software (Bioquant Image Analysis, Nashville, TN) 
and the following parameters were derived: osteoblast and osteoclast number per bone 
surface (N.Ob/BS and N.Oc/BS, 1/mm), the percentage of osteoblast and osteoclast 
surface (Ob.S/BS and Oc.S/BS, %), and adipocyte number per bone marrow area 
(N.Adi/Ma.Ar, 1/mm2) [18, 19]. Additionally, blood in OVX animals was collected via 
cardiac puncture at the time of euthanasia and left at room temperature for 30 min before 
being placed on ice and centrifuged at 2000×g for 10 min to separate sera. Serum tartrate-
resistant acid phosphatase 5b (TRAP) levels were determined by the RatTRAPTM 
(TRAcP 5b) ELISA immunoassay (Immunodiagnostic Systems, Scottsdale, AZ). 
2.2.4 Ex vivo µCT Scans and Uniaxial Compression Tests for the Lumbar Vertebra L2 
 The second lumbar vertebrae (L2) of long-term treatment groups were harvested 
and scanned by µCT (vivaCT40, Scanco Medical AG, Brüttisellen, Switzerland) at 10.5 
µm isotropic resolution. A 2.1 mm-thick trabecular VOI, which occupied the center 1/2 
of the vertebral body, was identified and subjected to analysis as described previously 
[20]. Subsequently, the vertebral body was cut at both ends of the growth plate using a 
low speed diamond saw (IsoMet, Buehler, Lake Bluff, IL) with water irrigation. A ~4-
mm specimen with two paralleled endplates was then obtained for the uniaxial 
compression test as described in [20]. The load-displacement curve generated from 
mechanical testing was used to calculate stiffness, peak load, and energy to failure. These 
mechanical properties at whole bone level were then normalized by vertebral size to 
calculate apparent-level mechanical properties including Young's modulus, toughness, 
and ultimate stress. 
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2.2.5 Cortical bone analysis and 4-point bending test of femoral shaft 
The right femurs of the long-term treatment groups were dissected after 
euthanasia. A 1.2-mm region of femur midshaft was scanned by μCT (µCT 35, Scanco 
Medical AG, Brüttisellen, Switzerland) at 6 μm image voxel size. Standard cortical 
parameters including cortical thickness (Ct.Th), cortical porosity (Ct.Po), cortical tissue 
mineral density (Ct.TMD), polar moment of inertia (pMOI), periosteal perimeter 
(Ct.Pe.Pm), and endosteal perimeter (Ct.En.Pm) were evaluated for a 0.3 mm thick 
region in the center of the midshaft. A destructive 4-point bending test was then 
performed at the midshaft region with a displacement rate of 1.8 mm/min with the outer 
supports being 26.56 mm apart and the inner supports being 8.84 mm apart (Instron 5542, 
Norwood, MA). The load-displacement curve generated from mechanical testing was 
used to calculate stiffness, peak load, Young's modulus, energy to failure, and post-yield 
energy to failure [21]. 
2.2.6 Statistical Analysis 
All statistical analyses were performed using NCSS 7.1.14 (NCSS, LLC, 
Kaysville, UT). Mean ± standard deviation (SD) are given for all the results. For 
longitudinal µCT image-based measurements, a two-way, repeated measures ANOVA 
was used to compare treatment groups over time. All comparisons were adjusted for 
baseline measures. In the presence of statistically significant main effects of time, 
treatment, and treatment*time interactions, post-hoc comparisons of between-group 
differences at each time point and within-group differences between different time points 
were made using a Bonferroni correction. For all cross-sectional group comparisons, a 
one-way ANOVA with a Tukey HSD post hoc test was performed to determine the 
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treatment effects among groups. For all analyses, a two-tailed p<0.05 was considered to 
indicate statistical significance. 
2.3 Results 
2.3.1 3-week PTH treatment benefits were maintained in intact rats upon 9-week 
discontinuation 
3-week PTH treatment to intact rats caused 29% and 33% increase in tibial 
BV/TV and Tb.Th, respectively, a 31% decrease in Conn.D, and a decrease of 0.69 in 
SMI (Figure 2-1). On the other hand, intact rats in the VEH group showed no changes in 
BV/TV, Tb.Th, Tb.Sp, or SMI, but an 8% decrease in Tb.N after 3 week saline treatment 
(Figure 2-1). BV/TV and Tb.Th were 34% and 26% greater, respectively, and SMI and 
Conn.D were 54% and 3% lower, respectively, in the PTH-treated animals compared to 
the VEH-treated animals at week 3 (Figure 2-1).  
Upon 9 weeks of discontinuation, the treatment benefits were maintained in 
BV/TV, Tb.Th, Tb.Sp, and Conn.D in PTH treated animals while Tb.N decreased by 5% 
(Figure 2-1). In contrast, continuous 9-week vehicle treatment resulted in 9% and 23% 
decrease in Tb.N and Conn.D, respectively, and a 15% increase in Tb.Sp (Figure 2-1). By 
the end of week 12, BV/TV and Tb.Th were 38% and 21% greater, and SMI was 40% 
lower in the PTH-treated animals compared to the VEH-treated animals (Figure 2-1).  
2.3.2 Early withdrawal from PTH is associated with a continuous anabolic window in 
OVX rats, but not in intact rats 
Before the treatment starts, 4-week osteopenia development in OVX rats caused a 
50%, 33% and 65% decrease in tibial BV/TV, Tb.N, and Conn.D, respectively, and an 
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increase of 1.3 in SMI (Figure 2-3). Compared to week 0, 3-week VEH treatment was 
associated with a 32% and 59% decrease in Tb.N and Conn.D, respectively, respectively, 
and a 71% increase in Tb.Sp (p<0.05). In contrast, 3-week PTH treatment effectively 
slowed down bone loss, causing a 30% and 39% increase in BV/TV and Tb.Th, 
respectively and no changes in SMI, Tb.Sp, and Conn.D (Figure 2-3). As a result, 
BV/TV, Tb.Th and Tb.N were 98%, 28% and 25% greater, respectively, and SMI was 
30% lower in the PTH-treated animals compared to VEH-treated animals at week 3. 
Surprisingly, 1 week after withdrawal (week 4), BV/TV, Tb.Th, and SMI continued to 
show trends of improvement, resulting in 7% and 8% increase in BV/TV and Tb.Th, 
respectively, and a decrease of 0.14 in SMI. This continuous anabolic effect upon 1-week 
withdrawal from PTH was only observed in OVX rats, but not in intact rats (Figure 2-2).  
2.3.3 3-week PTH treatment benefits diminished in OVX rats upon 9-week 
discontinuation 
Following the 1-week anabolic window, a rapid decline in BV/TV occurred from 
the second week (week 5) upon withdrawal from PTH in OVX rats. As a result, treatment 
benefit in BV/TV and SMI diminished and Tb.N became 23% lower compared to that at 
week 0. 9 weeks after discontinuation of PTH, the treatment benefits in trabecular bone 
completely diminished, with no difference between the PTH and VEH groups in any 
trabecular bone microstructure parameters (Figure 2-3). 
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2.3.4 Number of osteoblasts significantly reduced while number of osteoclasts and 
adipocytes increased upon withdrawal from PTH in OVX rats 
N.Ob/BS and Ob.S/BS were 117% and 107% greater in PTH-treated group than 
the vehicle-treated group (P3 vs. V3), respectively, while N.Oc/BS, Oc.S/BS and 
Adi.N/Ma.Ar were 55%, 52% and 69% lower in the P3 compared to the V3 group, 
respectively (Figure 2-4). After 1-week withdrawal from PTH, N.Ob/BS and Ob.S/BS 
decreased by 38% and 38 (P3V1 vs. P3), respectively, but remained 36% and 30% 
greater than the VEH group (P3V1 vs. V3, Figure 2-4). In contrast, no change was found 
in N.Oc/BS and Adi.N/Ma.Ar 1 week after discontinuation of PTH (P3V1 vs. P3, Figure 
2-4). 2-week after discontinuation of PTH, there was no remaining difference in 
N.Ob/BS, Ob.S/BS, N.Oc/BS and Oc.S/BS from the VEH group (P3V2 vs. V3) while 
Adi.N/Ma.Ar was still 29% lower than the VEH group (P3V2 vs. V3, Figure 2-4). Serum 
TRAP levels showed the similar trend as the N.Oc/BS and Oc.S/BS; however, no 
difference was detected between groups (Figure 2-4N).  
The responses of intact rats to the PTH treatment were similar to those of OVX 
rats, as demonstrated by 108% and 116% greater N.Ob/BS and Ob.S/BS, as well as 71% 
and 71% lower N.Oc/BS and Oc.S/BS in the PTH compared to the VEH group, 
respectively (P3 vs. V3, Figure 2-5). However, in contrast to rapid responses in bone cells 
to PTH discontinuation, there was no difference in any of osteoblast and osteoclast 
parameters between PTH-treated group and groups of 1- or 2-week after PTH 
discontinuation (P3 vs. P3V1, or P3 vs. P3V2, Figure 2-5). 
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2.3.5 Cyclic treatment regimen rescues PTH discontinuation-induced bone loss and 
extended treatment duration 
Without therapeutic intervention, significant bone loss and trabecular bone 
microarchitecture deterioration occurred in the proximal tibia of the VEH group over 18 
weeks, resulting in 61%, 58% and 87% decreases in BV/TV, Tb.N and Conn.D, and 25% 
and 147% increase in Tb.Th and Tb.Sp, respectively (Figure 2-6). In the PTH-VEH 
group, 9-week PTH treatment led to 99% and 92% increase in BV/TV and Tb.Th, 
respectively, a 18% decrease in Tb.N and a decrease of 1.35 in SMI (p<0.01, Figure 2-6). 
After 9-week discontinuation of PTH, BV/TV and Tb.Th underwent dramatic reductions 
of 305% and 151% while Tb.Sp underwent a substantial increase of 54%, and SMI 
underwent an increase of 1.21. By the end of week 18, PTH treatment benefit was 
completely lost, as reflected by no difference between the PTH-VEH and VEH groups in 
any trabecular bone microarchitecture parameters. In contrast, in the Cyclic PTH group, 
the first cycle of 3-week PTH on and 3-week off prevented reduction in BV/TV and led 
to a 55% increase in Tb.Th and a decrease of 0.55 in SMI. BV/TV and SMI stabilized 
and Tb.Th continued to increase during the 2nd and 3rd cycles. At week 18, BV/TV in the 
Cyclic PTH group was 45% and 65% greater than that of the PTH-VEH and VEH group 
while Tb.Th was 27% and 23% in the Cyclic PTH group vs. PTH-VEH and VEH group, 
respectively (p<0.05, Figure 2-6).  
By the end of week 18, there was no difference in any trabecular bone 
microarchitecture parameters or mechanics properties of the lumbar vertebra L2 between 
the VEH and PTH-VEH groups (Figure 2-7). In contrast, BV/TV of the Cyclic PTH 
group was 38% greater than that of the VEH group and Tb.Th was 26% and 16% greater 
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than that of the VEH and PTH-VEH groups, respectively (Figure 2-7). The Cyclic PTH 
group also achieved the greater mechanical properties of L2 than the VEH group both at 
the whole bone level (37% and 65% greater peak load and energy to failure, respectively) 
and at the apparent level (84% and 53% greater toughness and ultimate stress, 
respectively) which were calculated by normalizing whole-bone mechanics by vertebral 
size. 
In terms of femur midshaft, at the end of week 18, the Ct.Th in the Cyclic PTH 
group is 10% greater than the VEH group (Figure 2-8). There was no effect on other 
cortical bone microarchitecture parameters, including pMOI, porosity, TMD, Ct.Pe.Pm 
and Ct.En.Pm in the Cyclic PTH group compared to the PTH-VEH and VEH group, 
respectively (Figure 2-8). At the whole bone level, the Cyclic PTH group resulted in 25% 
and 43% increase in peak load and total energy to failure when compared to the VEH 
group (Figure 2-8).  
2.4 Discussion 
The results of this study indicate that significant tibial bone loss and bone 
microarchitecture deterioration occurred in estrogen-deficient animals in response to 
discontinuation of PTH treatment while no adverse effect was observed in intact rats, 
suggesting coupled effects between PTH withdrawal and the degree of bone remodeling 
dynamics. Intriguingly, there is a continuous anabolic window upon first week 
withdrawal from PTH in estrogen-deficient rats during which osteoblast activities 
outpaced osteoclast activities. In contrast, changes in bone cells, increased in number of 
osteoclasts and decreased in number of osteoblasts, 2 weeks after discontinuation of PTH 
treatment led to a decline in bone mass and bone microarchitecture. 9 weeks after 
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withdrawal, the PTH treatment benefits completely diminished. Additionally, the 
continuous anabolic window upon early withdrawal allowed the cyclic treatment regimen 
to rescue the bone loss, and efficiently maintain and improve upon the PTH treatment 
benefits on bone. The current findings suggest that the cyclic treatment regimen should 
be considered as a viable treatment option for osteoporosis. 
This study is the first to use an advanced in vivo µCT imaging and image analysis 
technique to longitudinally track changes taking place as a result of discontinuation of 
PTH administration at the proximal tibia in rats. Results from the clinical studies 
indicated that a rapid decline in bone mineral density and bone formation markers 
following the withdrawal of PTH in osteoporosis patients [12]. In addition, since PTH is 
approved for the treatment of osteoporosis in postmenopausal women and in men at high 
risk of bone fracture, it is of great clinical interest regarding how healthy patients’ 
responses to intermittent PTH administration as well as its discontinuation of PTH 
administration. Therefore, based on clinical observations, we hypothesized that the 
discontinuation of PTH administration would induce a substantial bone loss in both intact 
and estrogen-deficient rats. We first investigated the skeletal responses to the 
discontinuation of PTH administration in intact rats. Our approach using in vivo µCT 
imaging allowed for the longitudinal examination of local changes in the trabecular bone 
within a constant volume of interest (VOI). 4-5 month old intact female animals were 
used due to the minimal bone growth that occurs at this age. As expected, 3-week PTH 
treatment induced significant bone gain in intact animals. Surprisingly, there is no 
adverse effect in intact animals after 9-week withdrawal of PTH. As shown in Figure 2-1, 
similar consistency can be found for VEH and PTH-VEH groups in all microarchitecture 
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parameters in intact rats after week 3, indicating the PTH-treated animals maintain the 
bone mass and bone microarchitecture as well as the vehicle-treated animals do. 
Histology results also indicated that 3-week PTH treatment significantly induced 
osteoblast activities as well as reduced osteoclast activities. No changes were found in 
both osteoblast and osteoclast numbers after discontinuation of PTH administration. 
Taken together, the current findings suggest that it may be safe to treat healthy patients 
with PTH in clinical practice; however, further studies need to be performed to elucidate 
this unique mechanism.  
Based on the observation with no adverse effect on intact rats, we changed our 
focus to estrogen-deficient rats and examining their skeletal responses to the 
discontinuation of PTH administration. We used 4-5 month old female rats that were 
induced to develop estrogen-deficiency induced osteoporosis by OVX surgery for 4 
weeks. Before the treatment started, these rats had experienced rapid and substantial bone 
loss. During the 12 weeks of saline treatments, the vehicle-treated OVX rats continued to 
lose bone. In contrast, 3-week PTH treatment effectively slowed down bone loss for rat 
proximal tibia. Compared to the VEH group, PTH-treated rats showed elevations in 
osteoblast numbers and/or surface areas, and reductions in osteoclast numbers and/or 
surface areas, serum markers of bone resorption, and adipocyte numbers. Intriguingly, 
unlike intact rats, bone microarchitecture continued to show trends of improvement 1 
week after withdrawal from PTH. During this period, histomorphometry showed that 
osteoclast and adipocyte activities continued to be suppressed while osteoblast activities 
still remained although the number of osteoblasts started to decrease when compared to 
that after 3-week PTH treatment, suggesting that a continuous anabolic window upon 
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first week withdrawal from PTH in estrogen-deficient rats exists. Due to bone resorption 
exceeding bone formation as demonstrated in bone cell changes in Figure 2-4, bone mass 
and bone microarchitecture rapidly deteriorated starting 2 weeks after discontinuation of 
PTH treatment. As shown in Figure 2-3, 9 weeks after withdrawal from PTH, the 
treatment benefits completely diminished. However, serum TRAP analysis indicated 
more than doubled active osteoclasts in rats after 9-week withdrawal as compared to the 
VEH rats, potentially leading to more rapid bone loss after long-term PTH withdrawal.  
The anabolic window is a concept that, as evidenced by bone turnover makers in 
previous clinical observations [2, 11], bone formation increases after intermittent PTH 
administration with a delay in rise of bone resorption, therefore, bone formation 
exceeding resorption at this period. The intention is to prolong this initial bone-forming 
period to maximize the short-term efficacy of PTH and extend treatment duration. In the 
current study, we found that a continuous anabolic window was present 1 week after 
discontinuation of PTH administration. In order to fully utilize this benefit, a cyclic 
treatment regimen with repeated cycles of on and off daily injection of PTH may be able 
to maximize the efficacy of PTH and extend treatment duration. Indeed, in clinical 
practice, a cyclic treatment strategy has been proven to be more efficient for improving 
bone mineral density receiving alendronate [22-24]. Based on this idea, we hypothesize 
that a cyclic PTH treatment regimen will rescue the adverse effect on bone 
microarchitecture from discontinuation of PTH administration in estrogen-deficient rats. 
The µCT results showed that a cyclic treatment regimen with 3 repeated cycles of on and 
off daily PTH injection was sufficient for maintaining trabecular bone mass and 
microarchitecture to prevent deterioration due to estrogen deficiency and improved 
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trabecular thickness significantly in both tibial bone and vertebral bone. Additionally, the 
cyclic treatment regimen significantly improved the whole bone and apparent level 
mechanical properties, as indicated in peak load and energy to failure, in the lumbar 
vertebra and femur to be comparable with the VEH rats. Taken together, these results 
suggest that the cyclic treatment regimen can alleviate bone deterioration and extend the 
treatment duration.  
As discussed earlier, clinical studies observed bone formation increases after 
intermittent PTH administration before bone resorption increases. However, our current 
results showed that 3-week PTH treatment stimulated new bone formation on bone 
surfaces with suppressed resorption activities in estrogen-deficient rats. Similar 
observation was also reported in previous studies in the rat model. Liu and Kalu showed 
that the increase in trabecular induced by PTH was associated with increased in 
osteoblast number and decreased in osteoclast number of tibia in static bone 
histomorphometry in the estrogen-deficient rat model [25]. Sato et al. indicated that 2 
years of PTH treatment led to prominent osteoblasts but near absence of osteoclasts in 
femora, tibia and vertebra in histological sections of an intact rat model [26]. Our 
previous study in the estrogen-deficient rat model also demonstrated reduced bone 
resorption activities in PTH animals when compared to the VEH rats in static bone 
histomorphometry, serum resorption marker, and 3D in vivo bone dynamic 
histomorphometry [27]. Still, the reason behind the discrepancy between the clinical 
findings and rat model is not clear, which needs to be determined in future studies. 
In addition to the observation of the continuous anabolic windows after early 
withdrawal from PTH treatment, histomorphometry results showed a significant increase 
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in osteoclast number 2 week after discontinuation of PTH. Although cyclic PTH 
treatment regimen can alleviate bone deterioration, BV/TV in the Cyclic PTH group 
showed a trend of decline after 3 cycle of treatment probably due to elevated in osteoclast 
activities, N.Oc/BS, Oc.S/BS and serum TRAP, which are similar to the levels of the 
animals with 3-week PTH treatment followed by 2 weeks withdrawal. Clinically, it has 
been recommended that anti-resorptive treatment should be applied upon discontinuation 
of PTH to prevent bone loss. Therefore, it may be of interest to cyclically treat 
bisphosphonate followed by PTH. To understand the effect of the treatment strategy, 
further investigation is required. 
 In summary, we found that there is no adverse effect in intact animals while our 
results showed a significant bone loss and bone microarchitecture deterioration in 
estrogen-deficient animals after discontinuation of PTH administration. Additionally, 
there is a continuous anabolic window upon early withdrawal from PTH treatment, which 
supports a the cyclic PTH administration regimen to maximize the total duration and 
efficacy of treatment. Indeed, we found that cyclic PTH treatment regimen can efficiently 
prevent the deterioration in bone volume fraction and SMI due to estrogen-deficiency and 
led to a significant increased in trabecular thickness. Therefore, we concluded that the 







Figure 2-1. Intact Animals (A) Schematics of treatment strategies, (B) Representative 3D 
renderings of the proximal tibia of a VEH and PTH rat at weeks 0, 3, 6, 9, 12. (C-H) 
changes in tibial trabecular bone microstructure measurements in PTH and VEH groups. 
# indicates a significant difference between PTH and VEH groups (p<0.05). + indicates a 
significant difference between in VEH group between week 3 and week 12 (p<0.05). * 





Figure 2-2. Intact animals (A) Schematics of treatment strategies, (B-G) changes in tibial 
trabecular bone microstructure measurements in PTH and VEH groups. # indicates 





Figure 2-3. Estrogen-deficient animals (A) Schematics of treatment strategies, (B) 
Representative 3D renderings of the proximal tibia of a VEH and PTH rat at weeks -4, 0, 
3, 6, 12. (C-H) changes in tibial trabecular bone microstructure measurements in PTH 
and VEH groups. # indicates a significant difference between PTH and VEH groups 
(p<0.05). + indicates a significant difference between in VEH group between week 3 and 
week 12 (p<0.05).  * indicates a significant difference between in PTH-VEH group 







Figure 2-4. Estrogen-deficient animals (A-D) Osteoblasts (yellow arrows) and 
osteoclasts (black arrows) were shown in Goldner’s Trichrome staining of trabecular 
bone sections in OVX rats with 3-week VEH (V3) and PTH (P3) treatments, and 3-week 
PTH treatment followed by 1 and 2 weeks withdrawal (P3V1 and P3V2). Adipocytes 
were shown in H&E staining of trabecular bone sections in OVX rats at (E) V3, (F) P3, 
(G) P3V1, and (H) P3V2. Histomorphometric measurements of (I) osteoblast number 
(N.Ob/BS), (J) osteoblast surface (Ob.S/BS), (K) adipocyte number (Adi.N/Ma.Ar), (L)  
osteoclast number (N.Oc/BS), (M) osteoclast surface (Oc.S/BS), (N) ELISA analysis of 
serum concentration of bone resorption (TRAcP 5b) marker were measured for V3, P3, 




Figure 2-5. Intact animals (A-D) Osteoblasts (yellow arrows) and osteoclasts (black 
arrows) were shown in Goldner’s Trichrome staining of trabecular bone sections in OVX 
rats with 3-week VEH (V3) and PTH (P3) treatments, and 3-week PTH treatment 
followed by 1 and 2 weeks withdrawal (P3V1 and P3V2). Histomorphometry-based 
measurements of (F) osteoblast number (N.Ob/BS), (G) osteoblast surface (Ob.S/BS), 
(H) osteoclast number (N.Oc/BS), (I) osteoclast surface (Oc.S/BS) were measured for 








Figure 2-6. Estrogen-deficient animals in cyclic treatment regimens (A) Schematics of 
treatment strategies, (B) Representative 3D renderings of the proximal tibia of a VEH, 
PTH-VEH, and Cyclic PTH rat at weeks 0 and 18. (C-H) changes in tibial trabecular 
bone microstructure measurements in VEH, PTH-VEH, and Cyclic PTH groups. a 
indicates a significant difference between Cyclic PTH and VEH groups (p<0.05). b 
indicates a significant difference between PTH-VEH and VEH groups (p<0.05).  c 
indicates a significant difference between in Cyclic PTH and PTH-VEH groups (p<0.05). 
+ indicates a significant difference from week 0 in VEH group (p<0.05). # indicates a 
significant difference from week 0 in PTH-VEH group (p<0.05). * indicates a significant 






Figure 2-7. Comparisons between treatment groups in cyclic treatment regimens at the 
end of week 16 in trabecular bone microstructure and mechanical properties of lumbar 





Figure 2-8. Comparisons between treatment groups in cyclic treatment regimens at the 
end of week 16 in cortical bone microstructure and mechanical properties of femur. * 













































































Cyclic and Alternating Parathyroid Hormone and Alendronate Treatment 
Regimens Further Improve Bone Microarchitecture and Strength Beyond Daily and 
Cyclic Parathyroid Hormone Regimens 
 
3.1 Introduction 
 Teriparatide, recombinant human parathyroid hormone (rhPTH) 1-34, is the first 
FDA-approved anabolic agent for osteoporosis when administered intermittently. This 
anabolic agent is approved for the treatment of osteoporosis in postmenopausal women 
and in men at high risk of bone fracture [1, 2]. Unlike the anti-resorptive agents which 
suppress bone resorption through inhibition of osteoclast activities, its mechanism of 
action is to promote bone remodeling and to shift the balance of remodeling towards 
increased bone formation [3-5], thereby rapidly increasing bone mass and reducing the 
risk of fractures. In clinical practice, the recommended duration of PTH treatment is 18-
24 months. Despite showing the potent effects of promoting new bone formation, the 
anabolic effect of PTH treatment tends to reach a plateau over time [6-8] and the 
increased bone mineral density (BMD) in patients rapidly declines after discontinuation 
of  PTH administration [6, 9, 10]. Additionally, the cost of PTH is much higher than that 
of anti-resorptive agents, e.g. Bisphosphonates. However, since osteoporosis in 
postmenopausal women and elderly men is a life-long chronic condition, alternate 
treatment strategies for a more sustained, long-term therapeutic approach are of great 
clinical interest.  
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In order to enhance the PTH-induced bone formation, limit PTH-induced bone 
resorption, and reduce the cost of PTH treatment, a cyclic PTH regimen with or without 
antiresorptive agents which has been reported in several clinical trials [11-15] and in the 
murine model was proposed [16, 17]. The efficacy of the cyclic treatment regimen was 
compared to that of the standard daily treatment regimens. In humans, despite a lower 
PTH dosage, the cyclic PTH regimen consisting of repeated cycles of 3-month on and off 
daily PTH injection (20 or 25 μg/day) proved to be as effective as the standard daily 
injection of PTH on BMD in spine, femur and radius with prior and ongoing 
bisphosphonate alendronate (ALN) [12-14]. In mice, a repeated cyclic regimen consisting 
of one week of daily PTH injection (40 μg/kg/day) and one week off produced similar 
anabolic effects as a daily regimen. This is most notably depicted by the similarity in 
improved trabecular and cortical bone microarchitecture and cellular activities in the 
vertebra but not in the femur [16, 17]. Moreover, the efficacy of the cyclic PTH treatment 
regimen alone was also compared to that of the cyclic PTH and sequential antiresorptive 
regimens. The cyclic treatment regimen of PTH and antiresorptive agents, either 
calcitonin [15, 18] or denosumab [11], may suggest a beneficial effect in the lumbar spine 
or cortical bone. However, it is still not clear how bone quality and bone strength changes 
relative to the cyclic treatment regimens with or without antiresorptive agents. Although 
clinical trials and the murine model showed improvements with use of the cyclic 
treatment regimens, it would also be desirable to explore a model in rats that can monitor 
the temporal and spatial changes in bone in response to treatment. Additionally, using a 
rat model may allow for increased access to bone strength, especially of the vertebrae, 
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due to the technical difficulties presented by mouse models, e.g. small specimen size, and 
limited human cadaver samples.  
Our previous study discovered a continuous anabolic window of bone gain upon 
early withdrawal of PTH treatment, which was associated with elevation of osteoblast 
activity and suppression of osteoclast activity in the rat tibia (Figure 3-1). Based on this 
observation, we hypothesize that a repeated cyclic PTH treatment regimen, switching 
between weeks of daily PTH injection and saline injection would best utilize the anabolic 
window upon withdrawal. This would further result in extended treatment duration and 
significant improvement in bone mass, bone microarchitecture, and mechanical 
properties. Moreover, histomorphometic analyses of the rat tibial bone indicated an 
increase in osteoclast activity followed by the anabolic windows (Figure 3-1C). Based on 
this phenomenon, we further hypothesized that incorporation of an anti-resorptive 
treatment during the period of the cyclic regimen without PTH may further improve the 
treatment efficacy including bone mass, bone microarchitecture, and mechanical and 
material properties. According to the observations of the bone microarchitecture and bone 
cell activity (Figure 3-1) as well as bone resorption marker, tartrate-resistant acid 
phosphatase (TRAcP 5b) (data not shown), a cyclic regimen with repeated cycles of a 3-
week on and off daily PTH injection was chosen in this study. Therefore, the objective of 
this study was to investigate the effect of cyclic and alternating treatment regimens of 
daily injection of PTH and ALN on bone microarchitecture and mechanical competence 
in estrogen-deficient rats. We first investigated the skeletal responses to the cyclic and 
alternating treatment regimens of PTH and ALN at the proximal tibia in estrogen-
deficient rats using an advanced in vivo µCT imaging and image analysis technique. 
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After sacrifice, we evaluated the mechanical properties using a 4-point bending technique 
on the femur and an axial compression test on lumbar vertebrae L2, respectively, and 
determined material properties of lumbar vertebrae L1 using nanoindenatation.  
3.2 Materials and Methods 
3.2.1 Animals and treatment plans: skeletal effects by cyclic treatment regimens in 
estrogen-deficient rats 
All experiments were approved by the University of Pennsylvania's Institutional 
Animal Care and Use Committee. A total of 36 female Sprague Dawley rats were 
purchased (Charles River Laboratories, Willmington, MA) and received a bilateral 
ovariectomy (OVX) surgery at 16-17 weeks of age. The study began after a 4-week 
development of osteoporosis in the OVX rats. Five treatment regimens were examined in 
OVX rats: (1) a vehicle (VEH) group (n=6) receiving subcutaneous saline injections 
(150μL/day, 5 times per week) for 18 weeks, (2) a PTH-VEH group (n=7) receiving 
subcutaneous injections of PTH (40 µg/kg/day, 5 times per week) for 9 weeks followed 
by saline for 9 weeks, (3) a Cyclic PTH-VEH group (n=7) receiving 3 weeks of PTH 
followed by 3 weeks of saline injections, repeated for 3 cycles, (4) a Cyclic PTH-ALN 
group (n=8) receiving 3 weeks of PTH followed by 3 weeks of alendronate injections 
(ALN, 28 µg/kg/day, 2 times per week), repeat for 3 cycles, and (5) a Cyclic ALN-PTH 
group (n=8) receiving 3 weeks of PTH followed by 3 weeks of alendronate injections, 
repeated for 3 cycles. Rats were randomly assigned to different groups, housed in 
standard conditions in groups of three rats per cage. Experiments were performed 
unblinded. Rats were randomly assigned to different groups and housed in standard 
conditions in groups of three rats per cage. Experiments were performed unblinded.  
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3.2.2 In vivo µCT scans and analysis 
 The right proximal tibiae of all estrogen-deficient rats were scanned by μCT at 
week -4 (before OVX surgery), then at week 0, 3, 6, 9, 12, 15, and 18 (Figure 3-2A). As 
described in [19] and [20], rats were anesthetized (4.0/2% isoflurane), and the right leg of 
each rat was inserted into a custom holder to ensure minimal movement during the scan. 
A 4-mm region of the tibia, distal to the proximal growth plate, was scanned at 10.5 μm 
voxel size, 55 kVp energy, 145 µA intensity, 200 ms integration time, and 1000 
projections, using a 0.5mm Al filter and a standard, manufacturer-provided beam-
hardening correction algorithm, resulting in a total scan time of about 20 minutes and 
approximate radiation dose of 0.639 Gy per scan. 
 A landmark-initialized, mutual-information-based registration toolkit of an open 
source software (National Library of Medicine Insight Segmentation and Registration 
Toolkit, USA) was used to register the baseline and follow-up scans [21-23]. The volume 
of interest (VOI) chosen was approximately 2.3 mm distal from the growth plate and 
consisted of 200 slices corresponding to a 2.1 mm thick section of the trabecular 
compartment in the last scan (Week 18). Transformation matrices from the registrations 
were then applied to the VOI in order to locate the corresponding volume of trabecular 
bone in images from previous time points. Representative baseline and registered follow-
up images of each treatment group are shown in Figure 3-1B. 
 Bone voxels of each registered image were segmented from the bone marrow and 
background using Gaussian filtering (sigma=1.2 and support=2.0) and a global threshold 
corresponding to 564.8 mgHA/cm3. Bone microstructural parameters including bone 
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), 
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trabecular number (Tb.N), structure model index (SMI), and connectivity density 
(Conn.D), were evaluated for registered VOIs of weeks -4, 0, 3, 6, 9, 12, 15 and 18 in 
estrogen-deficient rats for all groups. 
3.2.3 Ex vivo µCT Scans and Uniaxial Compression Tests for the Lumbar Vertebra L2 
 After euthanasia, the second lumbar vertebra (L2) was harvested and scanned by 
µCT (vivaCT40, Scanco Medical AG, Brüttisellen, Switzerland) at 10.5 µm isotropic 
resolution. A 2.1 mm-thick trabecular VOI, which occupied the center 1/2 of the vertebral 
body, was identified and subjected to analysis as described previously [24]. Following the 
μCT imaging analyses, the vertebral body was cut at both ends of the growth plate using 
a low speed diamond saw (IsoMet, Buehler, Lake Bluff, IL) with water irrigation. A ~4-
mm specimen with two paralleled endplates was then obtained for the uniaxial 
compression test. The uniaxial compression test was performed in a displacement control 
with a speed of 0.03 mm/s using an Instron 5542 universal testing system (Instron, 
Norwood, MA). The specimen was compressed between two concentric cylindrical plates 
under room temperature. The load-displacement curve generated from mechanical testing 
was used to calculate stiffness, peak load, Young's modulus, ultimate stress, energy to 
failure, and post-yield energy to failure. 
3.2.4 Cortical bone analysis and 4-point bending test of femoral shaft 
The right femur was dissected after euthanasia. A 1.2-mm region of femur 
midshaft was scanned using μCT (µCT 35, Scanco Medical AG, Brüttisellen, 
Switzerland) at 6 μm image voxel size. Standard cortical parameters including cortical 
thickness (Ct.Th), cortical porosity (Ct.Po), cortical tissue mineral density (Ct.TMD), 
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polar moment of inertia (pMOI), periosteal perimeter (Ct.Pe.Pm), and endosteal 
perimeter (Ct.En.Pm) were evaluated for a 0.3 mm thick region in the center of the 
midshaft. A destructive 4-point bending test was then performed at the midshaft region 
with a displacement rate of 1.8 mm/min with the outer supports being 26.56 mm apart 
and the inner supports being 8.84 mm apart (Instron 5542, Norwood, MA). The load-
displacement curve generated from mechanical testing was used to calculate stiffness, 
peak load, Young's modulus, energy to failure, and post-yield energy to failure [25]. 
3.2.5 Nanoindentation tests for lumbar vertebra L1 
L1 was sectioned along the transverse plane by a low-speed diamond saw under 
water irrigation. The dissected surface of specimens was polished using silicon carbide 
abrasive papers with decreasing grit sizes (1200, 2400, and 4000 grits) and Al2O3 pastes 
(1 and 0.3mm) on soft polishing cloths in wet conditions. Sonication of the specimen in 
deionized water followed to remove debris. Then, the unpolished surface of the specimen 
was glued onto a polycarbonate holder with a fluid drainage system in a nanoindenter 
(Nano-XP; MTS, Oakridge, TN, USA) as described in previous studies [26-28]. All 
specimens were hydrated during nanoindentation. Central (C, center of a trabecula) and 
surface (S, ~10mm from the edge of a trabecula) regions of individual trabecular bone 
structures were identified using a light microscope incorporated within the nanoindenter, 
and 5-10 indents were made for those regions of each specimen using a pyramidal 
Berkovich tip of the nanoindenter. An indentation load rate corresponding to a 
displacement rate of 10 nm/s was applied up to a 500-nm indentation depth. Following 
the 30-s holding period, the indenter was unloaded with the same rate. Using the slope of 
the unloading force-displacement curve, nanoindentation elastic moduli for the inner 
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trabecular region (Ec) and the surface (Es) were measured using the Oliver-Pharr method 
[29]. Coefficient of variance was calculated for each treatment group to examine the 
heterogeneity of elastic modulus (Ecv) and hardness (Hcv), respectively.  
3.2.6 Statistical Analysis 
All statistical analyses were performed using NCSS 7.1.14 (NCSS, LLC, 
Kaysville, UT). Mean ± standard deviation (SD) are given for all the results. For 
longitudinal µCT image-based measurements, a two-way, repeated measures ANOVA 
was used to compare treatment groups over time. All comparisons were adjusted for 
baseline measures. In the presence of statistically significant main effects of time, 
treatment, and treatment*time interactions, post-hoc comparisons of between-group 
differences at each time point and within-group differences between different time points 
were made using a Bonferroni correction. A one-way ANOVA with a Tukey HSD post 
hoc test was performed to determine the treatment effect on vertebral trabecular bone, 
femoral cortical bone, and mechanical properties. For all analyses, a two-tailed p<0.05 
was considered to indicate statistical significance. 
3.3 Results 
3.3.1 Rescue bone deterioration in trabecular microarchitecture in the Cyclic Treatment 
Regimen  
During the 4-week osteopenia development, all bone microstructural parameters 
underwent a dramatic deterioration. Bone loss continued in the VEH group for 18 weeks. 
This tibial bone loss was associated with 61%, 58% and 88% decreases in BV/TV, Tb.N 
and Conn.D, respectively, and 26% and 147% increase in Tb.Th and Tb.Sp, respectively 
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(p<0.01, Figure 3-2CDEFH). In the PTH-VEH group, 9-week PTH treatment led to a 
100% and 92% increase in BV/TV and Tb.Th, respectively, a 19% and 31% decrease in 
Tb.N and Conn.D, respectively, and a decrease of 1.35 in SMI (p<0.01, Figure 3-
2CDEGH). After 9 weeks of PTH discontinuation, BV/TV, Tb.Th, Tb.N and Conn.D 
underwent a dramatic, 305%, 151%, 158% and 250% reduction, respectively, Tb.Sp 
underwent a substantial 54% increase, and SMI underwent an increase of 1.21 in SMI 
(p<0.01, Figure 3-2C-H). By the end of week 18, there were no difference between the 
PTH-VEH and VEH groups in BV/TV, Tb.N, Tb.Th, Tb.Sp and Conn.D (Figure 3-
2CDEFH). In contrast, in the Cyclic PTH-VEH group, the first cycle of 3-week on and 3-
week off PTH prevented reduction in BV/TV and led to a 51% increase in Tb.Th, 124% 
and 151% decrease in Tb.N and Conn.D, and a decrease of 0.55 in SMI. During the 2nd 
and 3rd cycles, BV/TV and SMI stabilized, Tb.Th and Tb.Sp continued to increase, and 
Tb.N and Conn.D continued to decrease. At week 18, BV/TV and Tb.Th in Cyclic PTH-
VEH animals were significantly greater and SMI was significantly lower than both PTH-
VEH and VEH animals (p<0.05, Figure 3-2CEG). Tb.N and Conn.D in the Cyclic PTH-
VEH group were significantly greater than the VEH group (p<0.05, Figure 3-2DH). 
Regarding the Cyclic PTH-ALN group, the first 3-week of PTH treatment led to a 55% 
and 50% increase in BV/TV and Tb.Th, respectively, a decrease of 0.56 in SMI (p<0.05, 
Figure 3-2CEG). The treatment benefit was maintained by treatment of ALN during the 
first cycle. BV/TV, Tb.Th and SMI continued to improve throughout the 2nd and 3rd 
cycles (p<0.05, Figure 3-2CEG). At the end of the 3 cycles of treatment BV/TV and 
Tb.Th increased by 120% and 94%, respectively, and SMI decrease by 0.73 when 
compared to week 0 (p<0.05, Figure 3-2CEG). In terms of the Cyclic ALN-PTH group, 
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BV/TV, Tb.Th, Tb.Sp and SMI were maintained during the first 3 weeks of ALN 
treatment (p<0.05, Figure 3-2CEFG). BV/TV and Tb.Th started to increase and SMI 
started to decrease after PTH treatment. BV/TV and Tb.Th increased by 91% and 70% , 
respectively, and SMI decreased by 0.57 during the 3 cycles of treatment (p<0.05, Figure 
3-2CEG). At week 18, the treatment benefit of PTH was further improved in both Cyclic 
PTH-ALN and Cyclic ALN-PTH groups in BV/TV, Tb.N, Tb.Sp, SMI and Conn.D when 
compared to the Cyclic PTH-VEH group (p<0.05, Figure 3-2CDFGH). Moreover, the 
Cyclic PTH-ALN group results in a thicker trabecular bone when compared to the Cyclic 
PTH-VEH and Cyclic ALN-PTH groups (p<0.05, Figure 3-2E). 
3.3.2 Improvements in the bone microarchitecture and mechanical competence in lumbar 
vertebrae L2 in Cyclic and alternating PTH and ALN groups  
At the end of week 18, BV/TV of the lumbar vertebra L2 of the Cyclic PTH-VEH 
group was 38% greater than that of the VEH group (Figure 3-3A). Additionally, Tb.Th of 
the lumbar vertebra L2 of the Cyclic PTH-VEH group was 26% and 16% greater than 
that of the VEH and PTH-VEH groups, respectively (Figure 3-3C). No difference was 
found in any trabecular bone microarchitecture parameters of the lumbar vertebra L2 
between the VEH and PTH-VEH groups (Figure 3-3A-F), and no difference was found in 
Tb.N, Tb.Sp, SMI and Conn.D of the lumbar vertebra L2 between the PTH-VEH group 
and the Cyclic PTH-VEH group (Figure 3-3BDEF). Moreover, both Cyclic PTH-ALN 
and Cyclic ALN-PTH treatments led to greater BV/TV, Tb.Th, and plate-likeness 
(indicated by reduction in SMI), and less Tb.Sp than the VEH, PTH-VEH and Cyclic 
PTH-VEH groups (Figure 3-3ACE). 
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At the whole bone level, the Cyclic PTH-VEH group resulted in 37%, 65%, 84% 
and 53% increase in peak load, energy to failure, apparent-level toughness and ultimate 
stress, respectively, in the lumbar vertebra L2 (Figure 3-3HIKL) when compared to the 
VEH group. Furthermore, peak load, energy to failure, apparent-level toughness and 
ultimate stress were 34%, 70%, 51%, 91% greater in the Cyclic PTH-ALN than the 
Cyclic PTH-VEH, and 28%, 65%, 49%, and 87% greater in the Cyclic ALN-PTH than 
the Cyclic PTH-VEH, respectively (Figure 3-3HIKL). No difference was found in in any 
apparent mechanical properties between the VEH group, the PTH-VEH group, and the 
Cyclic PTH-VEH group in the lumbar vertebra L2 (Figure 3-3G-L).  
3.3.3 Alterations in whole-bone femoral mechanical properties, but minimal effects on 
cortical microarchitecture at the femur midshaft and on tissue elastic modulus (E) and 
hardness of the Lumbar Vertebra L1 after the cyclic and alternating treatment regimens 
In terms of femur midshaft, at the end of week 18 there was no effect in any 
cortical bone microarchitecture parameters including Ct.Th, pMOI, porosity, TMD, 
Ct.Pe.Pm and Ct.En.Pm between groups (Figure 3-4A-F). At the whole bone level, the 
PTH-VEH group showed 14% and 22% improvement in stiffness and peak load, 
respectively, when compared to the VEH groups (Figure 3-4GH). The Cyclic PTH-VEH 
group resulted in 25% increase in peak load when compared to the VEH group (Figure 3-
4H). Moreover, the Cyclic PTH-ALN group showed 16%, 28%, 56% and 79% increase 
in stiffness, peak load, energy to failure and plastic energy, respectively, while the Cyclic 
ALN-PTH groups showed 14%, 21% and 51% increase in stiffness, peak load and energy 
to failure, respectively, when compared to the VEH group (Figure 3-4GHJ).  
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Regarding to the bone tissue properties, there was minimal change observed 
between groups in elastic modulus and hardness at the central region of the trabeculae 
and hardness at the surface region of the trabeculae (Figure 3-5ACG). There was a trend 
to show improvement in modulus in the PTH-VEH group at the surface of the trabeculae 
when compared to the VEH group (Figure 3-5E). Additionally, the elastic modulus at the 
surface of the trabeculae in the PTH-VEH group was 29% greater than the Cyclic PTH-
VEH group (Figure 3-5E). Moreover, there were no differences in tissue heterogeneity in 
modulus and hardness between groups at the surface of the trabeculae and at the central 
region of the trabeculae (Figure 3-5BDFH).   
3.4 Discussion 
This study used an advanced in vivo µCT imaging and image analysis technique 
to longitudinally track changes taking place at the proximal tibia in rats as a result of the 
cyclic PTH administration regimen. Our results showed that significant bone loss and 
bone microarchitecture deterioration occurred in estrogen-deficient animals after 
discontinuation of PTH treatment. 9 weeks after PTH withdrawal, the treatment benefits 
completely diminished with no difference in trabecular bone parameters between PTH-
VEH and VEH groups. The cyclic administration regimen in Cyclic PTH-VEH group 
alleviated bone deterioration and extended the total duration of treatment. However, 
despite continued increases in Tb.Th, the Cyclic PTH-VEH group did not continue to 
improve bone mass (reflected by BV/TV) or trabecular architecture (reflected by SMI). 
In addition, during the PTH treatment period of the second and third cycles, there was no 
improvement in BV/TV despite increases in Tb.Th, suggesting that the PTH treatment 
effects reached a plateau at this period due to high cellular activities not only in 
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osteoblasts, but also in osteoclasts. In order to further improve PTH treatment benefits, 
ALN was used during the off PTH period to inhibit osteoclast activities. Our results 
indicated significant improvement in bone microarchitecture and bone strength by both 
Cyclic PTH-ALN and ALN-PTH regimens when compared to the Cyclic PTH-VEH at 
the tibia and lumbar vertebrae L2. It was also shown that there was no influence on bone 
microarchitecture and bone strength by treatment sequence of Cyclic PTH-ALN and 
Cyclic ALN-PTH, except for effect on trabecular thickness. The current findings suggest 
that the alternating cyclic PTH and ALN treatment regimens should be considered as a 
viable treatment option for osteoporosis. 
We proposed the cyclic PTH administration regimen according to the findings in 
bone microarchitecture and bone cells activities in a rat model in our previous study: (1) a 
continuous anabolic window of bone gain was found upon early withdrawal of PTH 
treatment in the tibial bone (Figure 3-1A), and (2) osteoblast activity was elevated 
(Figure 3-1B) while osteoclast activity was suppressed (Figure 3-1C) during this period. 
On the other hand, the cyclic administration regimen in previous clinical and murine 
studies [11-18, 30] was proposed based on the observations of (1) modeling-based bone 
formation, i.e. bone formation without prior bone resorption during the first few weeks of 
daily PTH administration, (2) an anabolic window, i.e. elevation of bone resorption 
markers about 6 months after early stimulation of bone formation of daily PTH 
administration, and (3) a plateau of BMD in daily PTH treatment over time. Despite the 
differences in the initial aims of the previous clinical and murine studies, our findings led 
to the same treatment strategy, i.e. the cyclic PTH administration regimen.  
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Previous studies hypothesized that the cyclic treatment regimen might enhance 
the ultimate BMD accrual resulting from the modeling-based bone formation and 
overcome the tachyphylaxis of PTH treatment [12, 14, 16, 17, 30]. However, the cyclic 
PTH regimen with repeated cycles of 3-month on and off daily injection of PTH without 
prior or ongoing ALN did not show an increase in BMD more than standard daily PTH 
when considering either equal treatment dose or equal treatment time [13]. In addition, 
the cyclic PTH regimen with prior and ongoing ALN showed similar treatment effects as 
the standard daily injection of PTH on BMD in spine, femur and radius [12-14]. 
Therefore, the clinical studies did not show the enhancement in BMD using the cyclic 
PTH regimen. In the current study, the cyclic administration regimen in the Cyclic PTH-
VEH group produced the similar observations to the clinical studies when equal treatment 
dose was considered, i.e. 9-week daily treatment vs. 18-week cyclic treatment: the Cyclic 
PTH-VEH group did not show advantages in any bone microarchitecture parameter when 
compared to the PTH-VEH group. In contrast, regarding equal treatment time, i.e. at 
week 18, the Cyclic PTH-VEH group showed improvements in bone mass (reflected by 
BV/TV) and trabecular architecture (reflected by SMI) when compared to the PTH-VEH 
group. Based on this finding, the current study suggests that the cyclic administration 
regimen in the Cyclic PTH-VEH group can alleviate bone deterioration and extended the 
total duration of treatment in terms of bone microarchitecture. In the future studies, the 
DEXA scans may be also included to track the changes in BMD in the rat model.  
Additionally, previous studies also hypothesized that the cyclic and alternating 
treatment regimen might enhance and maximize the net anabolic effect of PTH by 
suppressing the bone resorption that anti-resorptive agents, either Calcitonin [15] or 
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Denosumab [11], were given sequentially after the PTH treatment. However, neither 
study showed greater BMD improvements in the cyclic and alternating regimen when 
compared to the cyclic PTH alone group [15] or the daily treatment group [11]. Hodsman 
et al. indicated that using calcitonin could be the wrong choice since it is a relatively 
weak anti-resorptive agent [15] while Cosman et al. indicated that the denosumab 
withdrawal effects may even out the following PTH treatment effects [11]. On the other 
hand, our results showed a significant improvement in bone microarchitecture with both 
Cyclic PTH-ALN & ALN-PTH regimens when compared to the Cyclic PTH-VEH at the 
tibia and lumbar vertebrae L2, indicating that the cyclic and alternating PTH and anti-
resorptive regimens further improved bone mass and bone microarchitecture beyond the 
Cyclic PTH-VEH regimen, suggesting that ALN may be the better choice as anti-
resorptive agent following PTH treatment. However, the reason for the discrepancy 
between the clinical findings and rat model is not clear, indicating a need for the future 
studies in this area. 
The clinical and murine studies reported that the cyclic treatment may show the 
beneficial effects in the lumbar spine and femur [11, 15, 16]. Hodsman et al. observed 
that there were very low incident vertebral fracture rates over 2-year cyclic and 
alternating PTH and Calcitonin treatments in osteoporosis patients [15]. Cosman et al. 
indicated that the cyclic PTH and Denosumab regimen might show a beneficial effect in 
the highly cortical bone sites in osteoporosis patients [11]. Iida-Klein et al. showed an 
increase in bone strength in the femur but not in the vertebrae in the intact murine model 
[16]. Our current results showed an enhancement in bone microarchitecture and bone 
strength in the cyclic administration regimen in Cyclic PTH-ALN and Cyclic ALN-PTH 
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groups in lumbar vertebrae L2, which may support Hodsman et al.’s findings, i.e. low 
vertebral fracture rate [15]. In order to further understand the material properties, a 
nanoindentation technique was performed on lumbar vertebrae L1. Unfortunately, no 
difference was found in elastic modulus or hardness. Moreover, our results did not show 
any structural or mechanical changes on femoral cortical bone, which was not consistent 
with previous findings [11]. The discrepancy may be due to the different properties of 
anti-resorptive agents, i.e. ALN vs. denosumab, and the animal models, i.e. rat vs. mice 
and estrogen deficiency vs. intact animals. Further studies need to be performed to 
address the differences.  
In summary, we found that the cyclic PTH treatment regimen in the Cyclic PTH-
VEH group can efficiently prevent bone loss and deterioration in trabecular 
microarchitecture due to estrogen-deficiency and led to a significant increase in 
trabecular thickness. The cyclic and sequential treatment of PTH and ALN can further 
improve the treatment efficacy of daily and cyclic PTH treatments on bone 
microarchitecture and bone strength and extend PTH treatment duration. Therefore, we 
concluded that the alternating cyclic PTH and ALN treatment regimens can alleviate 
bone deterioration and allow for extended the treatment duration and should therefore be 






Figure 3-1. Estrogen-deficient animals (A) changes in tibial trabecular bone 
microstructure measurements in PTH and VEH groups. # indicates a significant 
difference between PTH and VEH groups (p<0.05). + indicates a significant difference 
between in VEH group between week 3 and week 12 (p<0.05). * indicates a significant 
difference between in PTH-VEH group between week 3 and week 12 (p<0.05). 
Histomorphometric measurements of (B) osteoblast number (N.Ob/BS) and (C)  








Figure 3-2. Estrogen-deficient animals (A) Schematics of treatment strategies, (B) 
Representative 3D renderings of the proximal tibia of a VEH, PTH-VEH, Cyclic PTH-
VEH, Cyclic PTH-ALN and Cyclic ALN-PTH rat at weeks 0 and 18. (C-H) changes in 
tibial trabecular bone microstructure measurements in VEH, PTH-VEH, Cyclic PTH-
VEH, Cyclic PTH-ALN and Cyclic ALN-PTH groups. a indicates a significant difference 
between PTH-VEH and VEH groups (p<0.05). b indicates a significant difference 
between Cyclic PTH-VEH and VEH groups (p<0.05). c indicates a significant difference 
between in Cyclic PTH-VEH and PTH-VEH groups (p<0.05). d indicates a significant 
difference between Cylic PTH-ALN and VEH groups (p<0.05). e indicates a significant 
difference between Cyclic PTH-ALN and PTH-VEH groups (p<0.05). f indicates a 
significant difference between in Cyclic PTH-ALN and Cyclic PTH-VEH groups 
(p<0.05). g indicates a significant difference between PTH-ALN and Cyclic ALN-PTH 
groups (p<0.05). h indicates a significant difference between Cyclic ALN-PTH and VEH 
groups (p<0.05). i indicates a significant difference between in Cyclic ALN-PTH and 
PTH-VEH groups (p<0.05). j indicates a significant difference between in Cyclic ALN-
PTH and Cyclic PTH-VEH groups (p<0.05). + indicates a significant difference from 
week 0 in VEH group (p<0.05). # indicates a significant difference from week 0 in PTH-
VEH group (p<0.05). * indicates a significant difference from week 0 in Cyclic PTH-
VEH group (p<0.05). & indicates a significant difference from week 0 in Cyclic PTH-
ALN group (p<0.05). % indicates a significant difference from week 0 in Cyclic ALN-





Figure 3-3. Comparisons between treatment groups in cyclic treatment regimens at the 






Figure 3-4. Comparisons between treatment groups in cyclic treatment regimens at the 





Figure 3-5. Comparisons between treatment groups in cyclic treatment regimens at the 


















































































Differences in Material Properties of Trabecular Bone Tissue from Modeling- and 
Remodeling-Based Bone Formation in Rats 
 
4.1 Introduction 
Bone undergoes continuous changes during life through processes of bone 
remodeling and modeling. Both are inherently involved in the alteration of bone in 
response to environmental changes. Bone remodeling or so-called remodeling-based bone 
formation (RBF) plays a predominant role in maintaining skeletal health and mineral 
homeostasis [1]. During RBF, formation and resorption are tightly coupled, i.e., new 
bone forms over the resorbed bone surface [2]. Due to bone resorption preceding bone 
formation, the RBF site is characterized as a scalloped cement line with interruption of 
surrounding cement lines. On the other hand, bone modeling or so-called modeling-based 
bone formation (MBF) is a process that primarily alters overall bone size and shape in 
response to physiological influences. Previous studies suggested that MBF mainly occurs 
during growth, healing, and in response to external mechanical loading, and is less 
commonly found in the adult skeleton [3-7]. During MBF, formation and resorption are 
not tightly coupled, i.e., de novo bone formation without prior activation of osteoclastic 
resorption [2]. Since MBF occurs on quiescent bone surfaces without preceding bone 
resorption, the MBF site is characterized as a new bone packet with a smooth cement line 
without interruption of the surrounding collagen fibers.  
Recently, the concept of MBF has received increased attention due to the 
discovery of its involvement in several osteoporosis treatments [5, 7-11]. Lindsay et al. 
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reported that clinical treatment by teriparatide, intermittent injections of parathyroid 
hormone (PTH) 1-34, increases bone mass rapidly in 3 months by activating both RBF 
and MBF where MBF may account for more than 30% of bone gain by PTH [7]. 
Moreover, another recent study in rats and monkeys reported that Scl-Ab 
(Romosuzumab) improves aBMD primarily through a more than 10-fold increase in 
MBF without affecting the RBF rate, making MBF a promising target to treat 
osteoporosis [10]. Furthermore, MBF is not only elicited by anabolic agents but also 
responds to antiresorptive agents. Denosumab, a RANKL inhibitor, induces MBF at the 
endocortical bone surfaces [12], while Odanacatib, a cathepsin K inhibitor, stimulates 
MBF at the periosteal bone surfaces [11]. Additionally, studies have shown that MBF can 
be elicited on the trabecular bone surface by an anabolic agent with co-treatment of an 
anti-resorptive drug [5, 13-19]. 
While targeting MBF maximizes the net increase of bone quantity, there is limited 
knowledge on the quality of bone tissue that results from MBF. The only difference 
between MBF and RBF that the literature reported is structural morphometry, which was 
identified on a thin plastic section using polarized light [3]. It is unclear whether other 
aspects of tissue composition, structure, and mechanics of bone tissue from MBF differ 
from those of RBF, and whether such differences subsequently influence macro-scale 
bone fracture resistance. Moreover, most studies on bone tissue mechanics have focused 
on cortical bone [20]. The only mechanics reported on trabecular bone were the quasi-
static and dynamic nanomechanical properties [21]. However, there is a critical 
knowledge gap regarding the contribution of the MBF compared to the RBF to structure-
function relationships of trabecular bone tissue at multiple length scales. These 
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challenges may result from lacking reliable differentiation between MBF and RBF on a 
thick bone specimen, causing the inability to investigate the quality of the bone tissue 
generated through these two distinct cellular mechanisms. Therefore, the objective of this 
study was to (1) investigate the dynamics of MBF and RBF in response to PTH, (2) 
develop an imaging method that can be coupled with a mechanical testing platform for 
reliable identification and examination of material properties of RBF and MBF on thick 
bone sections, and (3) determine the differences in material properties of trabecular bone 
tissue from RBF and MBF. We hypothesize that the homogeneous collagen structure of 
the MBF site may lead to reduced heterogeneity of tissue material properties compared to 
RBF sites.  
4.2 Materials and Methods 
4.2.1 Animals and Treatment Plans 
All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Pennsylvania. A total of 17 female Sprague Dawley rats 
were used in this study. All rats were randomly assigned to different groups and housed 
in standard conditions in groups of three rats per cage. Experiments were performed 
unblinded. Intermittent PTH treatment (Human Recombinant PTH1-34, Bachem, 
Bubendorf, Switzerland) was administered subcutaneously 5 times per week to all 
animals at the dose of 20 µg/kg/day while Vehicle treatment was administered as 
subcutaneous injections of saline 5 times per week at the dose of 150 μL/day.  
The study began when the animals were at the age of 7 months due to minimally 
active bone accrual in rat skeleton at this age. To investigate the dynamic responses of 
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MBF and RBF, 12 intact female rats were used. Starting from day 0, the animals received 
daily subcutaneous injections of VEH or PTH for 3 weeks (Figure 4-1A). Alternatively, 
in order to determine the mechanical properties of trabecular bone tissue from RBF and 
MBF, 5 intact female rats were used. Starting from day 0, the animals received daily 
subcutaneous PTH injections for 3 weeks followed by 9 weeks of saline treatment 
(Figure 4-2A). Each rat was injected with a sequence of fluorochrome labels including 
calcein (green, G, 20 mg/kg, Sigma Aldrich, St. Louis, MO), alizarin complexone (red, R, 
30 mg/kg, Sigma Aldrich, St. Louis, MO), tetracycline (yellow, Y, 25 mg/kg, Sigma 
Aldrich, St. Louis, MO) in the order of G-R-Y-G at days -2, 5, 12, 19 (Figure 4-1A, 4-
2A). The animals were sacrificed on either day 21 (week 3, Figure 4-1A) or day 84 (week 
12, Figure 4-2A). Multi-color fluorochrome labeling allowed for accurate identification 
of formation sites of different tissue ages in the fluorescent image of the bone.  
4.2.2 Bone Histomorphometry of MBF and RBF for Thin Sections 
After euthanasia, the left tibia was harvested and fixed in 4% paraformaldehyde 
(PFA) at 4 °C for 48 hours. Samples were stored in 30% sucrose and then cryo-
embedded. Undecalcified specimens were sectioned in 8μm-thick sections as previously 
described [22] and attached to glass microscope slides using 1% chitosan adhesive. 
Mounted slides were rehydrated and scanned using Axio Scan Z1 (Zeiss, Oberkochen, 
Germany) to obtain fluorescent images (Figure 4-1B). After the first round of imaging, 
the sections were decalcified using Formical-2000TM decalcifier (StatLab, McKinney, 
TX) and the cement line and collagen fiber alignment were visualized under a polarizing 
microscope (Leica, Wetzlar, Germany, Figure 4-1C). Based on the structural 
morphometry and the overlaid images of fluorescent and polarized images (Figure 4-
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1DE), MBF and RBF sites were identified, and the histomorphometric measurements, 
including mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone 
formation rate (BFR/BS), were measured using OsteoMeasureTM (OsteoMetrics, Atlanta, 
GA). 
4.2.3 Sample Preparation for Thick Sections 
After sacrifice, the right tibia was harvested for methylmethacrylate (MMA) 
embedding without decalcification and then cut into a 4-mm-thick section along the 
coronal plane using a low-speed diamond saw (IsoMet, Buehler, Lake Bluff, IL) with 
water irrigation. The bone specimen surface was continuously manually polished using 1 
μm and 0.3 μm aluminum oxide (Al2O3) lapping discs in wet conditions and finally with 
a napless cloth with 0.06 μm non-crystallizing silica (SiO2) suspension. Sonication of the 
specimen in deionized water followed each step to remove debris.  
4.2.4 Fluorescence, Second Harmonic Generation, and Brightfield Microscopic Imaging 
for Thick Sections 
Fluorochrome labels (Figure 4-2B) of the entire bone specimen were captured 
with a fluorescence microscope (Axio Zoom, Carl Zeiss Inc., Thornwood, NY). The 
fluorochrome labels (Figure 4-2B) and collagen fibers (Figure 4-2C) of the entire 
trabecular bone region were observed with spectral confocal and multiphoton 
microscopes (Leica TCS SP8, Wetzlar, Germany) using a 20x/0.9 numerical aperture 
(NA) HC IRAPO motCORR water immersion objective. Calcein, alizarin complexone, 
tetracycline, and collagen fibers were imaged simultaneously. The individual images 
were overlaid (Figure 4-2D) with calcein shown in green, alizarin complexone in red, 
tetracycline in yellow and collagen fibers in cyan. Collagen fibers and cement lines were 
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obtained using two-photon, second harmonic generation (SHG) [21, 23], with an 
excitation wavelength at 930 nm and collection at 465 nm. The brightfield image (Figure 
4-2G) of the entire bone specimen was obtained with an optical microscope using 5x, 
0.13 NA objective (Axio Imager.A1m, Carl Zeiss Inc., Thornwood, NY). This brightfield 
image served as a reference image for co-registration with other imaging modalities. 
4.2.5 Nanoindentation 
A bright field image overlaid by a fluorescent image with MBF and RBF 
identified were used to guide test site selection (Figure 4-2F). 80-90% of bone formation 
sites were labeled with all 4 markers (G-R-Y-G) and only these sites (tissue age 10-12 
weeks) were chosen for indentation tests. The distance between labels is roughly 8 µm. 
10±2 MBF and 9±2 RBF sites were tested for each specimen. At each site, the 
indentation started from the pre-existing bone and ended at the PMMA (Figure 4-2H). 
The distance between 2 neighbor indents was 10-20 µm. The indent locations were 
precisely determined using an optical microscope with a 20X objective at a calibrated 
distance away from the indenter tip (10x zoom capacity, encoder resolution 500 nm, 
Figure 4-2G). As an example, indent marks performed on a MBF site are shown by SEM 
images (Figure 4-2IJ). Indentation tests were performed using a pyramidal Berkovich tip 
(Hysitron TI-950 TriboIndenter, Bruker, Billerica, MA) with a speed of 50 µN/s, held at 
a load of 2500 µN for 30 s, and unloaded at 50 µN/s. The indentation depth ranges from 
350-650 nm, which is considered sufficient to minimize the influence of surface 
roughness on the measurement. The elastic modulus (E) and hardness (H) were 
calculated based on the unloading portion of the load-displacement curve by the Oliver-
Pharr method [24, 25]. The full width at half maximum (FWHM) of the Gaussian curve 
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fit to the distribution of E and H was used to assess heterogeneity of each indentation 
parameter for each type of bone tissue. The coefficient of variance (CV) was also 
calculated to examine the heterogeneity of elastic modulus and hardness, respectively. 
4.2.6 Bone Mineralization Density Distribution Analysis  
After the nanoindentation tests, each bone specimen was subjected to quantitative 
backscattered electron imaging (qBEI) [26, 27]. An environmental scanning electron 
microscope (ESEM, FEI XL-30, Field Electron and Ion Company, Hillsboro, OR) 
equipped with a backscattered electron (BSE) detector was used to image the bone 
specimens. All images were captured with an accelerating voltage of 25 kV, a working 
distance of 13 mm, and a nominal magnification of 100X. The pixel resolution of the 
digital backscattered electron image was 0.375 µm per pixel. All images were taken 
under the same brightness and contrast condition. Carbon (Z=6) and Aluminum (Z=13) 
were used to calibrate the greyscale level with the atomic number [27, 28]. Weight % 
Calcium (wt%Ca) standardization was achieved by using osteoid with 0% Ca and pure 
hydroxyapatite with 39.86% Ca (Z=14.06) as reference points [26, 27, 29]. By registering 
the qBEI image with the fluorescent maps (Figure 4-2K), histograms of wt%Ca 
distribution for the entire MBF and RBF sites were contoured and separately calculated 
to derive the mean and heterogeneity of calcium distribution for each type of tissue. 
Furthermore, histograms of wt%Ca distribution of an 80-pixel region at the pre-existing 
bone, MBF and RBF, next to each indentation location (Figure 4-2H) were calculated to 




4.2.7 Statistical Analysis 
All statistical analyses were performed using NCSS 7.1.14 (NCSS, LLC, 
Kaysville, UT). Mean ± standard deviation (SD) are given for all the results. A one-way 
ANOVA with a Tukey HSD post hoc test was performed to determine the treatment 
effect on mechanical properties. For all analyses, a two-tailed p<0.05 was considered to 
indicate statistical significance. 
4.3 Results 
4.3.1 Bone Histomorphometry 
Mineralizing surface (MS/BS) between MBF and RBF did not differ in the 
vehicle (VEH)-treated 7-month-old female (Figure 4-1F). 3-week PTH treatment led to 
7.7 fold greater MBF-induced MS/BS compared to the VEH group in intact female rats 
(Figure 4-1F). On the other hand, PTH resulted in 3.6-fold greater RBF-induced MS/BS 
compared to the VEH group in intact female rats (Figure 4-1F). However, no difference 
in MAR between MBF and RBF was found in either VEH- or PTH groups (Figure 4-1G).  
4.3.2 Bone Tissue Mechanical Properties and Tissue Heterogeneity 
26±4, 22±3, and 26±4 indents were performed for MBF, RBF, and the pre-
existing bone of each specimen, respectively. No difference in elastic modulus or 
hardness was found between MBF and RBF. However, both MBF and RBF had lower 
elastic modulus (18.7% and 20.6%) and hardness (25.1% and 23.1%) than pre-existing 
bone (Figure 4-3AD). Surprisingly, the EFWHM of MBF was 27.4% and 27.9% greater 
than that in RBF and pre-existing bone, respectively (Figure 4-3B), indicating increased 
heterogeneity in MBF. Similar results were also found in the ECV (Figure 4-3C). In 
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contrast, there was no difference in HFWHM among MBF, RBF and pre-existing bone 
(Figure 4-3E). In terms of the HCV, MBF exhibited greater heterogeneity in hardness than 
pre-existing bone (Figure 4-3F). Furthermore, the dynamics of bone tissue maturation, 
i.e., 9-10 weeks, 10-11 weeks and 11-12 weeks, was evaluated in E and compared 
between MBF and RBF sites (Figure 4-4). MBF sites showed a greater degree of 
mineralization than RBF sites (Figure 4-4), which may indicate why MBF sites have 
greater heterogeneity (Figure 4-3BC).  
4.3.3 Bone Mineralization Density Distribution  
wt%Ca was calculated next to each indentation location. No difference in wt%Ca 
was found between MBF and RBF. There was no difference in wt%Ca among MBF, 
RBF and pre-existing bone (Figure 4-3G). In terms of the heterogeneity of wt%Ca, there 
was no difference between MBF and RBF (Figure 4-3H). However, the heterogeneity of 
wt%Ca (%CaFWHM) in pre-existing bone was greater than that in both MBF and RBF 
(Figure 4-3H). Regarding wt%CaCV, there was no difference between groups (Figure 4-
3I). 
4.4 Discussion 
Previous rodent and clinical investigations were referenced and either double 
labeling or quadruple tetracycline labeling methods were used to identify and 
differentiate between MBF and RBF sites of trabecular bone on plastic-embedded, 
undecalcified thin bone sections. Those studies first used fluorochrome labels to locate 
the new bone formation sites and then observed cement lines at these sites using 
transmission light or polarized light on Villanueva bone stained sections [4] or toluidine-
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blue stained sections [6]. Bone formation was designated as MBF if the underlying 
cement line was smooth and RBF if the cement line was scalloped.  
Several studies [16-18, 31-34] including ours [35-37] evaluated the effects of 
PTH with inhibited or absent osteoclasts in rodent bone and observed a significant 
anabolic response to PTH, thus, indicating that MBF accounts for a substantial fraction of 
PTH-induced bone formation in rodent bone. Using these criteria and methods, our first 
study investigated the dynamics of MBF and RBF of PTH and provided direct evidence 
showing that MBF and RBF were identified in 7-month-old PTH-treated female rats by 
employing a series of multi-color fluorochrome injections. These results suggest that both 
MBF and RBF contribute to skeletal homeostasis in the adult rat skeleton, and PTH 
exerts its anabolic actions through both MBF and RBF.  
However, in addition to morphological analysis, the contribution of the MBF 
compared to the RBF for structure-function relationships of trabecular bone tissue is 
critical. Without a reliable method to differentiate MBF and RBF on a thick bone 
specimen, the quality of the bone tissue generated through these two distinct cellular 
mechanisms cannot be investigated. This current study is the first to investigate the 
mechanical aspects of bone tissue resulting from MBF and RBF of trabecular bone on 
thick bone sections using a novel microscopic imaging and a nano-scale mechanical 
testing platform. Our novel imaging platform overcame this limitation for identifying 
MBF and RBF sites on a thick bone section, thereby allowing for testing subsequent 
tissue mechanical properties on the identified MBF/RBF sites. Similar to the previous 
studies on thin sections, the new bone formation sites were identified using fluorochrome 
labels. Instead of using transmission light or polarized light, the SHG imaging was 
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utilized to observe the collagen fiber alignment and determine the cement lines to 
differentiate MBF and RBF using the same criteria.  
We further refined the identification criteria using a 3D stack of SHG and 
fluorescent images. Based on the SHG imaging, about 10% of bone formation sites 
cannot be reliably differentiated into either MBF or RBF on thick sections. Moreover, the 
literature suggested that some RBF sites belong to overflow MBF (oMBF), where new 
bone formation extends beyond the limits of the RBF (Figure 4-5). Therefore, the sites 
with precise characteristics of MBF and RBF were included in this study. Nevertheless, 
because of the existence of oMBF, some of the formation sites may be erroneously 
interpreted to be MBFs occurring on the smooth surface based on the observed X-Y plane 
of the bone surface. In contrast, in the adjacent planes along the z-axis, a scalloped 
cement line may be present. We confirmed all MBF and RBF sites using a 3D stack of 
SHG and fluorescent images to examine the collagen fibers and cement lines up to 50 µm 
in depth (Figure 4-6). 
In optimizing our indentation protocol, the significant improvements in this study 
were the calibration and the indentation depth. The indentation depth on previous studies 
[20, 21] using the indentation machine, Bruker Hysitron TI-950, ranged from 50 to 250 
nm due to the calibration on the fused silica. However, since the surface roughness is 
around 50 nm based on the size of polishing particles, no-crystallizing silica (SiO2) 
suspension, the indentation depth may not be deep enough to eliminate the effects on the 
surface roughness. Therefore, in order to minimize the influence of surface roughness on 
the measurement, a magnesium alloy was chosen for the calibration standard in this study 
because the elastic modulus of the magnesium alloy is 45GPa, which is closer to that of 
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the bone specimens when compared to fused silica, 72GPa. By using the magnesium 
alloy as the calibration standard, the indentation depth ranges from 350 to 650 nm, which 
is deep enough to eliminate the effect on surface roughness.  
Based on the structural differences between MBF and RBF, we initially 
hypothesized that MBF has lower heterogeneity in tissue mechanical properties than 
RBF. While we observed no difference in the mean value of E and H between bone tissue 
from MBF and RBF, surprisingly, the current finding indicated greater heterogeneity in 
nano-scale E and H in bone tissue from MBF than those from RBF and pre-existing bone. 
Furthermore, we found that the degree of mineralization was greater in MBF compared to 
that in RBF. It has been suggested that bone tissue heterogeneity plays a critical role in 
determining bone tissue toughness and fracture resistance [4]. Therefore, the bone 
mineral density distribution (BMDD) was tested to determine the mechanisms behind the 
difference of the dynamics of bone tissue maturation. We further refined the protocol to 
measure the BMDD by qBEI. Previous studies measures the BMDD using carbon-coated 
specimens [27]. In order to keep the specimens intact, the ESEM was used; therefore, the 
specimens were scanned without conducted coating. It is still possible to indent the 
specimens after ESEM scanning. Due to greater heterogeneity and degree of 
mineralization in MBF using nanoindentation tests, the greater wt%Ca and heterogeneity 
were thought to be consistent with the indentation test results. However, no difference 
between MBF and RBF was found in bone mineral distribution. This inconsistency could 
be due to the bigger analyzing region compared to the indentation region, and therefore 
has to be further tested. 
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Although this study was the first of its kind to examine the mechanical properties 
of trabecular bone tissue from MBF and RBF on thick bone sections, several limitations 
exist, beginning with a small sample size of 5. This limitation may prevent apparent 
generalized mechanical properties between bone tissue from MBF and RBF. Second, the 
specimens were manually polished. Manual-polished specimens may result in an 
unparalleled specimen surface, i.e., a tilted bone surface, causing long scanning time and 
the inaccuracy of z-stack SHG imaging. Third, BSE imaging was taken after 
nanoindentation. In bone specimens, the compositional changes associated with bone 
tissue maturation depend on the mineral content, causing the grayscale level difference 
[38], e.g., the output image with a brighter grayscale level indicates higher mineral 
content at that region and vice versa. Since the ESEM was used in this study, the bone 
specimens were kept intact without coatings. ESEM imaging should be used to assist in 
identifying MBF and RBF sites along with the SHG imaging. Therefore, a modified 
protocol is proposed here. First, an automatic polishing method by a machine should be 
used to obtain a parallel, non-tilted, bone surface. Second, a region of interest (ROI) in 
the bone specimen is identified using a fluorescent microscope to determine bone 
formation sites. Third, SHG imaging and ESEM imaging are taken to identify MBF and 
RBF sites at the same ROI. Fourth, based on these identification sites, the indentation 
locations are chosen and the indents are performed at these locations. Finally, ESEM 
imaging can be utilized to examine the calcium distribution next to the indentation 
locations.  
In summary, we developed an innovative microscopic imaging and nano-scale 
mechanical testing platform to examine the mechanical properties of trabecular bone 
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tissue from MBF and RBF on thick bone sections. We found greater heterogeneity in 
nano-scale E and H in bone tissue from MBF than those from RBF and pre-existing bone. 
We also found that the degree of mineralization was greater in MBF compared to that in 
RBF. Our results suggest that targeting MBF in the adult skeleton may not only 
maximize the capacity of net bone volume increase, but also lead to high tissue quality 
toward better fracture resistance. Importantly, targeting MBF may be a more efficient 
strategy for osteoporosis treatment. 
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4.5 Figures  
 
Figure 4-1. (A) Drug treatment and multiple fluorochrome injection plan. Representative 
MBF and RBF sites on a thin section under (B) Fluorescent Imaging, (C) Polarized 
Imaging for cement lines, and (D) Overlaid image of (B) and (C) of a trabeculae; (E) A 
schematic representation of (C). MBF highlighted in green and RBF in red (F) MS/BS 
and (G) MAR of MBF and RBF in response to 3-week treatments of VEH and PTH in 





Figure 4-2. (A) Drug treatment and multiple fluorochrome injection plan. A guidance 
map for identification of MBF and RBF and for the subsequent nanoindentation test and 
quantitative backscattered electron imaging (qBEI). (B) Fluorescence, (C) Second 
harmonic generation, and (D) A overlaid image of (B) and (C) of trabecula with MBF 
and RBF on a thick bone section; (E) A schematic representation of (D): Green: MBF; 
Red: RBF. (F) A bright field image overlaid with fluorescent image. (G) An indentation 
on a MBF site shown under a bright field microscope equipped with a nano-indenter. (H) 
A schematic representation of selections of indentation locations on     MBF,     pre-
existing bone, and     PMMA, and     locations of analyzing the bone mineralization 
density distribution (I) A secondary electron image by SEM. (J) Indent marks (shown in 





Figure 4-3. Comparisons between MBF, RBF, and pre-existing bone tissue for (A) E, (B) 






Figure 4-4. Degree of bone tissue mineralization.           indicates the regression of the 































































































































Summary and Future Work 
 
5.1 Summary 
Millions of people suffer from osteoporosis and related symptoms in the United 
States. The current treatment strategies are either inducing bone formation using anabolic 
agents or inhibiting bone resorption via antiresorptive agents. However, neither of these 
strategies is ideal for osteoporosis treatment. Therefore, it is of great interest to 
understand the mechanisms behind existing treatment options to better develop effective 
treatment strategies. In this thesis, we began with understanding the structural and 
developmental changes as well as withdrawal effects on the first FDA approved anabolic 
agent, rhPTH (1-34). As a result of observing a continuous anabolic window, we 
proposed a potential effective treatment strategy, the short cycles of PTH and 
antiresorptive treatment regimen, which may lead to an increase in the number of newly 
activated modeling-based bone formation (MBF) sites. Since recent studies suggested 
that MBF may be a potential target of osteoporosis treatment, we developed an imaging 
method coupled with a mechanical testing platform to examine the quasistatic 
nanomechanical properties to compare MBF and remodeling-based bone formation 
(RBF) sites on thick bone sections. 
5.1.1 Chapter Two Summary 
Intermittent parathyroid hormone (PTH) is the first FDA approved anabolic agent 
for osteoporosis treatment. In clinical practice, the recommended duration of PTH 
treatment is 18-24 months. Despite the potent effect of intermittent PTH treatment on 
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promoting new bone formation, BMD rapidly decreases upon discontinuation of PTH 
administration. To uncover the mechanisms behind this adverse phenomenon, we first 
examined the changes in tibial bone microarchitecture in both intact and ovariectomized 
(OVX) rats using in vivo µCT. Significant tibial bone loss and bone microarchitecture 
deterioration occurred in estrogen-deficient animals in response to discontinuation of 
PTH treatment while no adverse effect was observed in intact rats. Intriguingly, there is a 
continuous anabolic window upon the first week of withdrawal of PTH in estrogen-
deficient rats during which no significant change occurred in the number of osteoclasts 
despite the number of osteoblasts starting to decrease. 2 weeks after discontinuation of 
PTH treatment, changes in bone cells, an increase in the number of osteoclasts and a 
decrease in the number of osteoblasts, led to a decline in bone mass and bone 
microarchitecture. 9 weeks after withdrawal, the PTH treatment benefits completely 
diminished. However, the observation of the continuous anabolic window upon early 
withdrawal from PTH offers a new mechanism in support of a cyclic administration 
regimen with repeated cycles of on and off PTH treatment. The cyclic treatment regimen 
allows for rescue of the bone loss and efficiently maintains and improves upon the PTH 
treatment benefits on bone as well as whole-bone mechanical properties. Overall, this 
study provided a thorough characterization of the precise structural changes to investigate 
the discontinuation of PTH in both intact and estrogen-deficient rat models as well as a 
cyclic administration regimen. It was unexpected that no adverse effect was shown at the 
tibial bone on the intact rat after discontinuation of PTH, further indicating that PTH 
could be a viable treatment for a healthy individual. Moreover, our study discovered a 
continuous anabolic window upon early withdrawal from PTH supporting the short cyclic 
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administration regimen of PTH. The current findings suggest that the cyclic treatment 
regimen can alleviate bone deterioration and extend the treatment duration. 
5.1.2 Chapter Three Summary 
Bone mineral density rapidly decreases upon withdrawal from intermittent PTH 
treatment despite its positive effects on promoting bone formation. Our previous study 
showed a continuous anabolic window during the first week of PTH discontinuation in 
OVX rats, which offers a new mechanism supporting a cyclic administration regimen 
with repeated cycles of on and off PTH treatment to maximize the treatment duration. 
Moreover, osteoclast number showed a significant increase following the anabolic 
window. Therefore, we hypothesized that incorporating an antiresorptive treatment 
during the off-PTH period of the cyclic treatment regimen may further improve the 
treatment efficacy. To test this hypothesis, we directly compared changes in bone 
structure following OVX surgery in rats with short cycles of PTH and Alendronate 
(ALN) regimens. In vivo μCT-based longitudinal evaluation of trabecular microstructure 
indicated that cyclic and alternating PTH-ALN significantly improved bone volume 
fraction (BV/TV), trabecular thickness (Tb.Th), and structural model index (SMI) at the 
proximal tibial trabecular bone when compared to the estrogen deficient animals with or 
without short cycles of PTH and saline treatment. Additionally, short cycles of PTH and 
ALN alternating regimens showed greater whole bone mechanical properties at lumbar 
vertebrae L2. Taken together, results from this study indicate that the cyclic and 
alternating treatment of PTH and ALN significantly improve the treatment efficacy on 
bone microarchitecture and bone strength and extend PTH treatment duration.  
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5.1.3 Chapter Four Summary 
 Activation of modeling-based bone formation (MBF), i.e., bone formation (BF) 
on quiescent surfaces, has been identified as an important mechanism by which anabolic 
agents, e.g., rhPTH1-34, rapidly elicit new BF. However, the quality of the bone tissue 
generated from MBF vs. remodeling-based BF (RBF, BF coupled with osteoclast 
resorption) is unclear. To identify MBF and RBF, we injected calcein (green, G), alizarin 
complexone (red, R), and tetracycline (yellow, Y) fluorochrome labels to 7-mo-old adult 
female rats in a G-R-Y-G sequence on days -2, 5, 12, and 19 (PTH 20 μg/kg on days 1-
21), followed by euthanasia on day 84. Based on fluorochrome labels, cement lines, and 
collagen fiber alignment under fluorescence and second harmonic generation (SHG) 
microscopes, BF sites were identified as MBF (smooth cement line and uniform collagen 
fibers) or RBF (scalloped cement line with interrupted surrounding collagen fibers) on 
the 4-mm-thick PMMA sections of the rat tibia. We hypothesize that the homogeneous 
collagen structure of MBF may lead to reduced heterogeneity of tissue material properties 
when compared to RBF. Compared to VEH, PTH treatment led to marked increases in 
both MBF- and RBF-induced mineralizing surface (MS/BS). MBF showed greater 
MS/BS than RBF with no difference in mineral apposition rate (MAR). Nanoindentation 
tests were performed on PTH-treated specimens where BF sites were labeled with all 4 
markers (G-R-Y-G, tissue age 10-12 wks). At each BF site, individual indents were 
performed first on the pre-existing bone, then on the MBF or RBF site, and lastly on the 
PMMA as internal controls. While no difference in elastic modulus (E) or hardness (H) 
was found between MBF and RBF, both MBF and RBF had lower E and H vs. pre-
existing bone. Surprisingly, the full width at half maximum (FWHM) in E (EFWHM) of 
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MBF was greater than that of RBF and pre-existing bone, respectively, indicating 
increased heterogeneity in MBF. Similar results were also found for the coefficient of 
variance (CV) of E (ECV) and H (HCV). In this study, we successfully developed an 
imaging method that can be coupled with a mechanical testing platform for reliable 
identification and examination of material properties of MBF and RBF on thick bone 
sections. Our findings indicate greater heterogeneity in nano-scale E and H in bone tissue 
from MBF than those from RBF and pre-existing bone, rejecting our original hypothesis. 
Our results suggest that targeting MBF may not only maximize the net bone mass 
increase but also lead to higher tissue heterogeneity. 
5.2 Future Directions 
Based on the results reported here, several potential future directions should be 
considered for this research field. These can be broadly classified into few categories: (1) 
investigation of adverse effects and mechanisms on other anabolic agents, e.g., 
Abaloparatide (PTHrP) and Romosozumab (Scl-Ab); (2) determination of the structure-
function relationship of bone tissue formed through MBF and RBF; (3) elucidation of the 
cellular mechanisms behind the dynamic responses of MBF and RBF in short cycles of 
anabolic agents and anti-resorptive agents. 
5.2.1 Investigation of adverse effects and mechanisms including structural changes and 
biological changes on approved anabolic agents, e.g., Abaloparatide (PTHrP) and 
Romosozumab (Scl-Ab) 
In 2017 and 2019, the FDA approved the second and third anabolic agents for 
osteoporosis treatment, Abaloparatide (PTHrP) and Romosozumab (Scl-Ab). Like 
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teraparitide (PTH), both new anabolic agents increase bone mineral density (BMD) by 
enhancing bone formation [1-4]. However, the treatment efficacy of both drugs, 
compared to teraparitide, on bone microarchitecture are unclear. Moreover, due to the 
diminished treatment benefit of PTH upon discontinuation in estrogen-deficient bone, it 
is of interest to investigate the withdrawal effects on the new drugs. Our pilot study 
evaluating longitudinal changes in tibial trabecular bone after PTHrP withdrawal at the 
proximal tibia also indicated a continuous anabolic window upon early discontinuation of 
PTHrP and a rapid bone loss afterward. In conjunction with the results in chapter two, 
PTH and PTHrP efficiently increase bone volume by thickening the remaining 
trabeculae. Both treatments require follow-up with antiresorptive therapy upon 
discontinuation to maintain their treatment benefits. Further investigation into a cyclic 
administration regimen of PTHrP would be beneficial. Furthermore, in addition to 
structural changes, the biological changes of trabecular bone, e.g., cellular levels and 
molecular levels, using ovariectomized rats after discontinuation of anabolic drugs 
remains unclear and should be evaluated in future investigations.  
5.2.2 Determination of the structure-function relationship of bone tissue formed through 
MBF and RBF 
In chapter four, we developed a novel imaging method, allowing for reliable 
identification and examination of material properties of RBF and MBF on thick bone 
sections. Future studies are required to examine the material composition of bone tissue 
from MBF and RBF to elucidate the structural mechanisms behind the different material 
properties between bone tissues from MBF and RBF. Addressing the mechanisms behind 
the difference in the dynamics of bone tissue maturation structural mechanisms, this will 
105 
 
provide new insights into the structure-function relationship of MBF, RBF and pre-
existing bone. Dynamic nanomechanical properties: The viscoelastic properties can play 
an important role in bone [5, 6]. Loss tangent is an indicator of viscous energy loss within 
the material under conditions of dynamic loading. Using a dynamic mechanical analyzer 
(DMA) system in nanoindenter will allow for testing of the dynamic nanomechanical 
properties. The loss tangent values will be derived to obtain a loss tangent at each 
frequency for MBF, RBF and pre-existing bone sites. Mineral distribution analysis: 
Quantitative backscattered electron imaging (qBEI) will be used to test the bone mineral 
distribution. By registering the qBEI image with the fluorescence maps, histograms of 
wt%Ca distribution for MBF and RBF sites of different tissue ages, and pre-existing bone 
can separately be calculated to derive the mean and heterogeneity of calcium distribution 
for each type of tissue. Additionally, bone tissue adjacent to each indented site can be 
tested to validate the nanoindentation results. Compositional properties: Raman 
Spectroscopy imaging can be utilized to determine the compositional properties including 
mineral-to-matrix ratio (area ratio of phosphate ν1 and amide III), carbonate-to-phosphate 
ratio (area ratio of carbonate ν1 to phosphate ν1), and mineral crystallinity (the inverse of 
the FWHM of a Gaussian fit of the phosphate ν1 peak). Bone tissue adjacent to each 
indented site can be imaged at a spatial resolution of ~1 µm. The compositional 
properties can be derived based on the normalized spectra [7-9] for each type of bone 
tissue. Collagen alignment analysis: Polarization-sensitive second harmonic generation 
(P-SHG) imaging is a promising and powerful imaging modality. This technique has 
been used to characterize collagen fiber orientations on biological tissues [10, 11] and to 
106 
 
diagnose a wide range of diseases [11, 12]. In the future study, P-SHG can be used to 
map the degree of alignment of the collagen fibers [13] within regions of MBF and RBF.  
5.2.3 Elucidation of the cellular mechanisms behind the dynamic responses of MBF and 
RBF in short cycles of anabolic agents and anti-resorptive agents  
Due to the observation of the rapid bone loss after discontinuation of anabolic 
agents, it has been suggested that antiresorptive agents should be used in treatment after 
the discontinuation of anabolic agents [14, 15]. Additionally, studies have shown that 
modeling-based bone formation can be stimulated on the trabecular bone surface using 
intermittent PTH with co-treatment of an anti-resorptive drug [15-21]. Together with the 
conclusion in chapters three and four, short cycles of anabolic agents and anti-resorptive 
agents may increase the number of newly activated MBF, retain the RBF and quiescent 
bone, and improve bone tissue heterogeneity. Therefore, further investigation of the 
cellular mechanisms behind the dynamic responses of MBF and RBF will provide more 
insights into the potential osteoporosis target, modeling-based bone formation.  
5.3 Final Conclusions 
 The search for effective osteoporosis treatment targets continues. Modeling-based 
bone formation (MBF) could be of significant value. However, many unknowns still 
exist, emphasizing the need for further investigations to shed light on MBF. The studies 
in this thesis provided important information on structural, cellular and mechanical 
effects on the skeleton in both intact and estrogen-deficient bone. The findings and the 
methods reported here create the frameworks for future MBF investigations. In addition, 
the translation of these findings and methods to a clinical setting will not only further 
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improve the understanding of MBF but also provide insights into developing effective 
treatment strategies. 
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